60 YEARS OF POMC

Adrenal and extra-adrenal functions
of ACTHNicole Gallo-Payet^{1,2}¹Division of Endocrinology, Department of Medicine, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Quebec, Canada²Centre de recherche clinique Étienne-Le Bel of the Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec, CanadaCorrespondence
should be addressed
to N Gallo-Payet**Email**
nicole.gallo-payet@usherbrooke.ca

Abstract

The pituitary adrenocorticotrophic hormone (ACTH) plays a pivotal role in homeostasis and stress response and is thus the major component of the hypothalamo–pituitary–adrenal axis. After a brief summary of ACTH production from proopiomelanocortin (POMC) and on ACTH receptor properties, the first part of the review covers the role of ACTH in steroidogenesis and steroid secretion. We highlight the mechanisms explaining the differential acute vs chronic effects of ACTH on aldosterone and glucocorticoid secretion. The second part summarizes the effects of ACTH on adrenal growth, addressing its role as either a mitogenic or a differentiating factor. We then review the mechanisms involved in steroid secretion, from the classical Cyclic adenosine monophosphate second messenger system to various signaling cascades. We also consider how the interaction between the extracellular matrix and the cytoskeleton may trigger activation of signaling platforms potentially stimulating or repressing the steroidogenic potency of ACTH. Finally, we consider the extra-adrenal actions of ACTH, in particular its role in differentiation in a variety of cell types, in addition to its known lipolytic effects on adipocytes. In each section, we endeavor to correlate basic mechanisms of ACTH function with the pathological consequences of ACTH signaling deficiency and of overproduction of ACTH.

Key Words

- ▶ adrenal cortex
- ▶ zona glomerulosa
- ▶ zona fasciculata
- ▶ ACTH
- ▶ adrenocorticotropin
- ▶ MC2
- ▶ signaling
- ▶ cortisol
- ▶ glucocorticoid
- ▶ aldosterone
- ▶ ion channels
- ▶ cytoskeleton
- ▶ extracellular matrix

*Journal of Molecular
Endocrinology*
(2016) **56**, T135–T156

Introduction

The adrenocorticotrophic hormone (ACTH) (39 amino acids (a.a.)) results from PC1/3 cleavage of the proopiomelanocortin (POMC) precursor and may be further cleaved by proconvertase 2 to generate α -melanocyte-stimulating hormone (α -MSH) (a.a. 1–13 of ACTH) (Raffin-Sanson *et al.* 2003, Dores *et al.* 2014). ACTH is mainly produced in the corticotrophic cells from the anterior pituitary, but is also produced in the brain, adrenal medulla, skin, and placenta (Vrezas *et al.* 2003, Bicknell 2008, Evans *et al.* 2012). As ACTH is the

most potent stimulus of the adrenal cortex, most of the knowledge on its mechanism of action derives from studies on the adrenal cortex or ACTH receptor-expressing cells.

The adult adrenal cortex is divided into three zones. At the periphery, under the capsular of tight connective tissue, the thin zona glomerulosa (ZG) consists of small cells organized as loops around capillaries, then the zona fasciculata (ZF) occupies the major part of the cortex, with cells that change progressively from radial centripetal columns, separated by sinusoids to a less-organized

network, becoming the zona reticularis (ZR). Cells from the adrenal cortex, as for all steroid-producing cells, are characterized by the presence of lipid droplets containing cholesteryl esters (CE) as precursors for steroidogenesis. These lipid droplets are scarce and small in ZG and becomes large and numerous in the outer fasciculata. In the cells from ZR, lipid droplets vary in size and shape (NussDorfer 1986, Vinson 2003). The adrenal glands are also highly vascularized (Vinson & Hinson 1992, Bassett & West 1997) and innervated by pre- and post-ganglionic sympathetic fibers, sensory fibers, and vagal fibers (Vinson *et al.* 1994, Holgert *et al.* 1998).

Overview of the ACTH-MC2R complex

The ACTH receptor, called melanocortin 2 receptor (MC2R), cloned in 1992 (Mountjoy *et al.* 1992), is a member of the family of five melanocortin receptors (MCRs), which include MC1, MC3, MC4, and MC5 that bind the MSH peptides. This distinct family of G protein-coupled receptors (GPCRs) act primarily through cAMP as a second messenger. MCRs are characterized by their unusually short sequence and the absence of highly conserved a.a. residues or motifs common to most GPCRs. MC2R is both the smallest MCR and the smallest known GPCR (297 a.a). Compared with other MCRs, MC2R is unique in that it binds ACTH only and does not possess affinities for other melanocortins (for reviews see Cone 2006, Dores 2009).

Another important progress in understanding how the ACTH-MC2R complex is able to stimulate cAMP production was the discovery of melanocortin-2 receptor accessory protein 1 (MRAP, often called MRAP1) by Metherell *et al.* (2005). In the absence of melanocortin-2 receptor accessory protein (MRAP), MC2R is non-functional (i.e. there is no production of cAMP, even if the receptor is correctly addressed to the cell membrane). We (Kilianova *et al.* 2006, Roy *et al.* 2007) and others have been able to decipher the mechanisms of expression and regulation of MC2R in melanocortin-2 receptor accessory proteins (MRAPs) expressing cells. The role of MRAP1 as well as the relative roles that the various forms of MRAPs identified thereafter has been documented in several recent reviews (Hinkle & Sebag 2009, Cooray & Clark 2011, Jackson *et al.* 2015, Clark 2016). Another particularity is that ACTH treatment of adrenocortical cells (4 h or more) increases the expression of MC2R (Penhoat *et al.* 1989, Mountjoy *et al.* 1994), as well as the level of MRAP and MRAP2 (Hofland *et al.* 2012). Short-term stimulation of MC2R-expressing cells with ACTH (15–60 min) induces MC2R desensitization and internalization through a

PKA-dependent mechanism (Rani *et al.* 1983, Baig *et al.* 2001), possibly acting in synergy with PKC (Kilianova *et al.* 2006, Chan *et al.* 2011, Gallo-Payet & Battista 2014).

Studies on structure–activity relationships have determined that ACTH(1–16) is the minimal sequence required for ACTH binding to MC2R and downstream signaling (Kapas *et al.* 1996, Chen *et al.* 2007). In addition, some ACTH fragments not only lack activity, but act as competitive antagonists of full-length ACTH, as is the case for ACTH(7–38) (Kapas *et al.* 1996). The latter is now known as corticotropin-inhibiting peptide (CIP) (Li *et al.* 1978). However, ACTH(11–24) has been described as a competitive antagonist of ACTH(1–39) (Seelig *et al.* 1971, Kapas *et al.* 1996), whereas in another study, it has been reported to stimulate corticosterone production of ZF cells and aldosterone production of ZG cells, in addition to potentiating the effects of ACTH(1–39) (Szalay *et al.* 1989). The a.a. 6–9 (HFRW sequence) is essential for cAMP production and has been called the ‘message sequence’, whereas the a.a. 15–18 (KKRR sequence) essential for the binding of ACTH to MC2R has been called the ‘address sequence’ (Dores 2009). Mutations in the HFRW or KKRRP motifs of ACTH (Liang *et al.* 2013) in the *POMC* gene, or a non-functional PC1/3 in corticotropic cells (Seidah & Chretien 1999), abrogate the hypothalamo-pituitary-adrenal (HPA)-activating axis (Dores 2009, Dores *et al.* 2014). The properties of MC2R are reviewed by Peng Loh and Robert Dores in this issue (Cawley *et al.* 2016, Dores *et al.* 2016).

Illustrating the importance of these sequences in ACTH action, we discovered a mutation (p.R8C; HFRW>HFCW) that abolishes ACTH binding and cAMP production in MC1R-, MC2R-, and MC4R-expressing cells (Samuels *et al.* 2013). ACTH-R8C was found to be immunoreactive, but failed to bind and activate cAMP production in MC2R-expressing cells, whereas α -MSH-R8C failed to bind and stimulate cAMP production in MC1- and MC4-expressing cells. Discovery of this mutation indicates that, in humans, the His⁶Phe⁷Arg⁸Trp⁹ (HFRW) sequence is important not only for cAMP activation but also for ACTH binding to MC2R (Samuels *et al.* 2013).

Pathological consequences of MC2R deficiency for the adrenal cortex

Mutations in the *MC2R* gene are responsible for 25% of familial glucocorticoid deficiency (FGD) and mutations in the *MRAP* gene, encoding the MC2R accessory protein MRAP, are responsible for 20% of FGD (Meimaridou *et al.* 2013, Jackson *et al.* 2015). FGD is an autosomal

recessive disorder resulting in cortisol deficiency, due to resistance of the adrenal cortex to the action of ACTH. Postmortem examination of adrenal glands from FGD patients demonstrated a disorganization of glomerulosa cells and almost completed absence of ZF and ZR, suggesting that MC2R and/or MRAP may be important for the development of adrenal zonation (Gorrigan *et al.* 2011).

Effects of ACTH on the adrenal cortex

Steroids produced by the adrenal cortex

The adrenal cortex produces several steroid hormones, the most important being cortisol (glucocorticoid), aldosterone (mineralocorticoid), and androgen precursors. All these hormones are essential for homeostasis as well as survival. Disorders of the adrenal glands lead to classical endocrinopathies such as Cushing's syndrome,

Addison's disease, hyperaldosteronism, and the syndromes of congenital adrenal hyperplasia (CAH) (Miller & Auchus 2011).

Aldosterone is produced exclusively in the ZG due to the specific expression of P450 aldosterone synthase (P450aldo, CYP11B2), whereas cells from the ZF and ZR, which express P450c11 β -hydroxylase (P450c11, CYP11B1), synthesize glucocorticoids (GC) (cortisol in humans, bovine, and dogs and corticosterone in rodents, except hamsters that produce cortisol). However, the ZR, through P450c17,20 lyase (CYP17A1), produces the androgen precursors, dehydroepiandrosterone (DHEA), its sulfated derivative DHEAS (which circulates at concentrations 1000 times higher than DHEA) and androstenedione, at least in humans and higher primates, but not in rodents (Vinson 2003, Arlt & Stewart 2005) (Fig. 1). The relative thickness of each zone is correlated with the efficacy and daily production of steroids (Rainey 1999).

Figure 1

Steroidogenesis in the three zones of the adrenal cortex. (A) Hematoxylin- and eosin-stained section of an adult rat adrenal gland. Scale bar, 100 μ m. (B) Free cholesterol is recruited in three enzymatic pathways, leading to aldosterone in zona glomerulosa; corticosterone or cortisol in zona fasciculata and zona reticularis; and dehydroepiandrosterone (DHEA), DHEAS, and androstenedione in zona reticularis. Cholesterol is cleaved in the inner mitochondrial membrane by P450 cholesterol side-chain cleavage enzyme (P450scc/CYP11A1) into pregnenolone. Further steps involve the enzymes indicated in the figure. The steps indicated in red take place in the mitochondria and the steps indicated in blue take place in the endoplasmic reticulum. Data from Arlt & Stewart PM (2005).

Indeed, the amount of aldosterone needed to control salt balance is 100- to 1000-fold lower than that needed to control carbohydrate metabolism, and in humans, daily production of aldosterone is in the order of pmol/L (100–150 g/day), compared with the nmol/L range for cortisol/corticosterone (10–20 mg/day) and mol/L range for DHEAS (up to 20 mg/day) (Arlt & Stewart 2005).

Mineralocorticoids, such as aldosterone, stimulate sodium reabsorption, hence maintaining blood volume and pressure in sodium-depleted conditions. Excessive aldosterone secretion not only leads to hypertension and electrolyte imbalance, but is also associated with cardiometabolic complications (Funder & Reincke 2010, Briet & Schiffrin 2011). However, GC (cortisol, corticosterone, and cortisone) are implicated in a broad range of metabolic functions, including anti-inflammatory responses, stress response, and behavior (Chan *et al.* 2011, Corander & Coll 2011), increasing blood glucose concentrations through their action on glycogen, protein, and lipid metabolism (Arlt & Stewart 2005). However, chronically elevated GC levels alter body fat distribution, increase visceral adiposity, and are responsible for several metabolic abnormalities leading to metabolic syndrome (Dallman *et al.* 2004).

Role of ACTH in corticosteroid rhythmicity

Circulating GC levels are higher during the activity period (day for diurnal species and night for nocturnal species), and peak levels are linked to the beginning of the activity period (for rats, nadir in the morning and peak in the late afternoon). These circadian changes in ACTH and corticosterone are associated with circadian expression of steroidogenic genes and those involved in ACTH signaling (Park *et al.* 2013). In addition to the driving role established by the suprachiasmatic nucleus (SCN) (Chung *et al.* 2011, Ota *et al.* 2012), sensitivity of the adrenal glands to ACTH stimulation could be regulated through adrenal splanchnic innervation (Ulrich-Lai *et al.* 2006a) and by intra-adrenal circadian clockwork (Son *et al.* 2008). Interestingly, in rats, although the *Mc2r* gene is induced by ACTH, *Mc2r* mRNA is at its highest levels in the morning, when ACTH is minimal. By contrast, MRAP expression peaks in the evening, consistent with the circadian rhythm of ACTH. These data suggest that it is the circadian rhythm of MRAP, rather than of MC2R, that results in increased adrenal sensitivity to ACTH in the evening (Park *et al.* 2013). By contrast, the circadian rhythm of plasma aldosterone in recumbent normal subjects on a regular

diet is independent of ACTH, but regulated by the activity of plasma renin (Williams *et al.* 1972). An exception is found in patients with aldosterone-producing adenomas, where short-term decrease in ACTH (by administration of dexamethasone) eliminates or markedly alters the circadian variation of plasma aldosterone, suggesting that patients with primary aldosteronism have a circadian rhythm of plasma aldosterone mediated by changes in ACTH (Kem *et al.* 1975).

Jet lag or sleep perturbations results in a transient mismatch between the internal circadian time and the external light–dark cycle. Over long periods, these changes are associated with increased body mass index and alterations in the levels of circulating insulin, glucose, and GCs (Van Cauter *et al.* 2008). Moreover, alterations in GC rhythmicity and dissociation of GC secretion from ACTH secretion occur during various pathological conditions, including Cushing's syndrome, metabolic syndrome, mood disorders, and even Alzheimer's disease (Bornstein *et al.* 2008, Chung *et al.* 2011, Russell *et al.* 2014).

Effects of ACTH on steroidogenesis

Under physiological conditions, cortisol and adrenal androgen secretion are controlled primarily by ACTH, although having a more complex action on ZG and aldosterone secretion. The response of adrenocortical cells to ACTH can be divided into two phases: the acute phase, which occurs within seconds to minutes, involves transcription-independent stimulation of adrenal steroid synthesis, although the more sustained phase affects not only steroidogenic capability, but also size and structural integrity of the gland, as evidenced by the atrophy observed after hypophysectomy or in POMC-deficient animals (Coll *et al.* 2004) (Chan *et al.* 2011, Corander & Coll 2011).

The acute response of ACTH involves mobilization and delivery of free cholesterol from lipid droplets to the inner mitochondrial membranes where it is metabolized by P450_{scc}/CYP11A1 to pregnenolone – the first enzymatic step in the steroid hormone biosynthetic pathway. The transfer of free cholesterol from the outer to the inner mitochondrial membrane is triggered by phosphorylation and activation of the steroidogenic acute regulatory protein (StAR) (Stocco 2000, Jefcoate 2002), the rate-limiting protein of steroidogenesis. In ZG cells, such effects also involve calcium (Ca²⁺)- and calmodulin-dependent processes (Cherradi *et al.* 1996).

StAR does not act alone but is part of a multi-protein complex, which includes translocator protein (TSPO) (Rone *et al.* 2009) but also arachidonic acid (AA) metabolites (Maloberti *et al.* 2007). Then, the various steps of steroidogenesis take place alternatively in mitochondria and in the endoplasmic reticulum (where the three cytochrome P450 enzymes and one hydroxysteroid dehydrogenase (3 β -HSD) are localized) and in a zone-specific manner, as illustrated in Fig. 1 (Stocco *et al.* 2005, Miller & Auchus 2011). Of note, steroids (which are lipolytic hormones) are immediately released after synthesis, in contrast to peptidic hormones, which are stored in secretory vesicles.

In ZF, chronic treatment with ACTH (from hours to days) increases the expression of a number of genes including those involved in cholesterol availability, through selective lipoprotein-derived cholesterol (Kraemer 2007, Hu *et al.* 2010) and synthesis of the enzymes required for steroidogenesis, including StAR (Fleury *et al.* 1998). These latter actions are mediated by various transcription factors, one of the most important being the nuclear receptor NR5A1/steroidogenic factor 1 (SF1) (required not only for the expression of most of the steroidogenic enzymes, but also for the development of the adrenal cortex) (Sewer & Waterman 2003, Schimmer *et al.* 2006, Schimmer & White 2010, Xing *et al.* 2010, Miller & Auchus 2011). Chronic treatment with ACTH also increases the volume of the adrenal glands and blood flow within it (Mazzocchi *et al.* 1986, Thomas *et al.* 2004). Chronic stress (which mimics chronic ACTH treatment) induces hyperplasia in the outer ZF and hypertrophy in the inner ZF, but reduces the size and properties of the ZG. These effects are associated with elevated corticosterone responses (Ulrich-Lai *et al.* 2006b).

Effects of ACTH on protection against reactive oxygen species accumulation

Intense steroidogenesis in ZF leads to oxidative stress due to lipid peroxidation, and to the production of reactive aldehyde metabolites such as isocaproaldehyde (Hornsby & Crivello 1983, Lefrançois-Martinez *et al.* 1999). This may explain the large quantity of endogenous anti-oxidant compounds (vitamin E, β -carotene, and vitamin C) (Hornsby & Crivello 1983) and the presence of enzymes implicated in detoxification of steroidogenesis by-products (Martinez *et al.* 2001) in the adrenal glands (Lefrançois-Martinez *et al.* 1999, Chinn *et al.* 2002). To prevent cell toxicity, these reactive oxygen species (ROS) are metabolized to isocaproic acid by a family of aldo-keto reductases (AKR), including *Akr1b8* and

Akr1b7 in mice and *AKR1B10* in humans (Lefrançois-Martinez *et al.* 1999, Pastel *et al.* 2012). These enzymes are highly expressed in the adrenal glands, and their levels of expression are correlated with the level of ACTH (Schimmer *et al.* 2007).

Another mechanism used by cells to circumvent the negative side effects of intense steroidogenesis is through induction of 24-dehydrocholesterol reductase (DHCR24) (a member of the flavin adenine dinucleotide (FAD)-dependent oxidoreductase family) (Sarkar *et al.* 2001). As for AKR1B7, in human and rat adrenocortical cells, SElective Alzheimer disease INDicator 1 (seladin-1) is more abundant in ZF/ZR than in ZG, and ACTH treatment increases its expression and its nuclear localization (Battista *et al.* 2009). Overall, chronic levels of ACTH increase transcription of the genes that encode the steroidogenic enzymes, but also those involved in ROS detoxification (such as AKR and seladin-1), thereby maintaining optimal steroid production and reduction of harmful lipid aldehydes (Lefrançois-Martinez *et al.* 1999).

Acute effect of ACTH on aldosterone secretion and consequences of chronic ACTH treatment

The role of ACTH in the ZG and in aldosterone secretion is subject to controversy and probably more complex than currently perceived. Indeed, *in vivo* studies suggest that ACTH is rather a weak stimulus of aldosterone secretion; however, based on *in vitro* studies, ACTH is the most potent stimulus of aldosterone secretion. Continuous intravenous administration of ACTH leads to a sustained stimulation of cortisol secretion but to a transient stimulation of aldosterone secretion, followed by a decrease in prestimulation levels by 72 h. By contrast, pulsatile infusion of ACTH leads to a stimulation of aldosterone secretion, which is maintained for up to 72 h (Seely *et al.* 1989). Moreover, aldosterone secretion is more sensitive to low doses of ACTH(1–24) than the secretion of cortisol or DHEA (Daidoh *et al.* 1995), especially in humans under conditions of low-sodium intake (Rayfield *et al.* 1973, Kem *et al.* 1975, Nicholls *et al.* 1975).

Moreover, sustained exposure to ACTH (2 days or more) leads to transformation of the ZG cells into ZF cells. From a mechanistic point of view, several mechanisms may explain this transient response of glomerulosa cells to ACTH. In primary cultures of bovine adrenocortical cells, a 2 h ACTH treatment was sufficient to increase 17 α -hydroxylase (P450c17) and 11 β -hydroxylase (P450c11) activity by 55-folds in mitochondria from

ZF cells, although the latter was reduced by 50% in mitochondria from ZG cells, as for 18-hydroxylase activity (P450c11B2). In addition, in ZG cells from adrenal glands of ACTH-treated rats (6 days, 2UI/day), Ang II receptors and Ang II-stimulated aldosterone are markedly decreased (Aguilera *et al.* 1981), whereas the production of deoxycorticosterone and precursor steroids is conversely increased, indicating a blockade in the late step of aldosterone synthesis (Bird *et al.* 1996). These functional changes are accompanied by a morphological transformation of ZG cells into ZF-like cells (Manuelidis & Mulrow 1973, Hornsby *et al.* 1974, Muller 1978, Crivello & Gill 1983, Pudney *et al.* 1984). In particular, mitochondria changed from an elongated shape with lamellar and tubular cristae to a homogeneous population of round or ovoid mitochondria with ovoid cristae, as in ZF cells (Armato *et al.* 1974, Riondel *et al.* 1987) (Vinson 2003, Corander & Coll 2011, Hattangady *et al.* 2012, Gallo-Payet & Battista 2014).

Effect of ACTH on adrenal growth

The adrenal cortex is a very dynamic organ, in which secretory activities correlate with morphology and structure according to external stimuli or environmental conditions. For example, a sodium-deficient diet increases width and volume of ZG, without affecting ZF. A study conducted with adrenals from 61 surgical/autopsy patients from 1 day old to 92 years old has revealed that the ZG was well developed in human adrenals from newborn to the third decade. However, after 40 years of age, an important decrease in ZG was observed. ZG cells become scattered and both ZG and ZF are surrounded by a progenitor zone, which has the ability to differentiate bidirectionally into either ZG-topped columns or ZF-topped columns, according to secondary aldosteronism or to exposure to severe stresses. These authors suggest that the involution of ZG with age may be due to the current high-sodium/low-potassium diet in humans compared with earlier human populations even as recently as 50 years ago (Aiba & Fujibayashi 2011).

However, ACTH deficiency decreases, while ACTH treatment increases the volume of ZF (Rebuffat *et al.* 1989, Thomas *et al.* 2004). Knockout of the *Mc2r* gene in mice leads to neonatal lethality in most of the animals, possibly as a result of hypoglycemia. Animals surviving to adulthood have a marked atrophy of the ZF. However, the ZG remains fairly intact, although aldosterone secretion was significantly decreased (Chida *et al.* 2007).

These results confirmed and extended the importance of the ACTH–MC2R complex in adrenal development, as in the production of corticosterone and probably aldosterone (Chida *et al.* 2007). Supporting this conclusion is the recent observation of high levels of expression of MC2R and MRAP in the undifferentiated zone, which contains stem cells (Gorrigan *et al.* 2011).

The mechanisms involved in adrenocortical remodeling are complex and sometimes redundant, with the aim of preserving or restoring homeostasis or coping with stress (Pihlajoki *et al.* 2015). There are indications that ACTH is involved in various aspects of the dynamic organization of the adrenal cortex, namely cell migration and proliferation. It is generally assumed that proliferation takes place either under the capsule (stem cell region), in the ZG itself, or in the outer part of ZF and that cell senescence occurs mainly in ZR (Wolkersdorfer & Bornstein 1998, Kim *et al.* 2009). To discriminate between the effect of ACTH on cell proliferation or on cell hypertrophy, Engeland and his group have used a 14-day chronic variable stress paradigm in adult male rats. They found that chronic stress induced hyperplasia in the outer ZF, hypertrophy in the inner ZF and medulla, and reduced cell size in the ZG. These effects were associated with elevated corticosterone responses to ACTH (Ulrich-Lai *et al.* 2006b). However, there are indications that proliferation is probably not mediated by ACTH, but rather by other POMC-related peptides. Indeed, *in vivo* immunoneutralization of circulating ACTH reduces corticosteroid levels, but increases mitogenesis (Estivariz *et al.* 1982); cell proliferation in the ZF in *Mc2r*-knockout mice is comparable to cell proliferation in wild-type mice (Chida *et al.* 2007), whereas in *Pomc*-knockout mice, the absence of cell proliferation results in the atrophy of adrenal glands (Coll *et al.* 2004, Karpac *et al.* 2005). Further in-depth investigations have revealed that the active domain of POMC-derived peptide is a small fragment, N-POMC (50–74) (also named γ 3-melanocyte-stimulating hormone, γ 3-MSH). This aspect is reviewed further in this issue by Andy Bicknell (Bicknell *et al.* 2001, Bicknell 2016).

In isolated cells in culture, ACTH inhibits cell proliferation to favor steroid secretion (Hornsby & Gill 1977, Mattos *et al.* 2011). It is now relatively well accepted that ACTH is preferentially a differentiation factor controlling steroid secretion rather than a proliferation factor. However, ACTH favors cell survival when viability is compromised, a protective effect occurring only when the adrenal glands are intact. Indeed, quartering of

the glands enhances basal apoptosis and, interestingly, abolishes ACTH-induced inhibition of apoptotic DNA fragmentation, without altering ACTH-induced corticosterone secretion. These data suggest that the global organ architecture is required for modulation of adrenal cell survival by ACTH (Carsia *et al.* 1997). In another study conducted in mice, adrenal atrophy was observed after 14 days of dexamethasone treatment: a condition that suppresses ACTH secretion. Such treatment induced an important decrease in adrenal weight and cellularity, due to inhibition of cell proliferation, induction of cell apoptosis, and progressive regression of the vascular network. These data support the concept that ACTH had a trophic action on the adrenal cortex through a dual mechanism involving antiapoptotic effect and effects on vasculature (Thomas *et al.* 2004).

Effect of ACTH on gene expression

All the above effects of ACTH have been confirmed by measurements of gene expression (Xing *et al.* 2011, Nishimoto *et al.* 2012, Rege *et al.* 2014). In this regard, the Y1 mouse adrenocortical cell line is a model that has been widely used to identify changes in gene expression after treatment with ACTH. This cell line shares many features with normal cells from the adrenal cortex (Rainey *et al.* 2004, Schimmer *et al.* 2006). For example, a 15K mouse cDNA microarray was used to identify genome-wide changes in gene expression after a 20 min ACTH treatment with effects measured 24 h later. ACTH affected the levels of 1275 annotated transcripts, of which 46% were up-regulated. Not surprisingly, the transcripts up-regulated in response to ACTH are those implicated in steroid biosynthesis and metabolism, transcription factors involved in the expression of the steroidogenic enzymes, and signaling molecules involved in the hormonal regulation of steroidogenesis. The transcripts down-regulated in response to ACTH are associated with DNA replication, mitotic activity, nuclear transport, and RNA processing. Such results are consistent with the growth-inhibiting effects of ACTH that are observed in Y1 cells under the conditions used in this study (Schimmer *et al.* 2006).

The signaling pathways of ACTH action

Although several second messengers have been described, the primary events following ACTH binding to MC2R is adenylyl cyclase (AC) activation and cAMP production together with Ca²⁺ influx. Thereafter, cAMP can directly

activate various protein kinases, including protein kinase A (PKA), protein kinase C (PKC), mitogen-associated protein kinase (MAPK), ion-channels, guanine nucleotide exchange factors, or transcription factors.

In addition to human or nonhuman adrenocortical cells, two cell lines have been widely used to investigate the most selective signaling pathways, namely the Y1 mouse adrenocortical cell line and the NCI-H295R cells, involved in aldosterone secretion (Rainey *et al.* 2004). Indeed, in NCI-H295R cells, the expression of CYP11B2/Ang II is high, but level of expression of MC2R is low, whereas in Y1 cells, the expression of CYP11B2 and Ang II receptors is low, but the expression of MC2R is high.

Cyclic AMP and Ca²⁺: lessons from structure–activity relationships

Since the pioneering work of Lefkowitz *et al.* (1970), several studies have shown that cAMP and Ca²⁺ interact closely through positive feedback loops to enhance steroid secretion (Fakunding *et al.* 1979, Fakunding & Catt 1980, Kojima *et al.* 1985a, Gallo-Payet & Payet 1989). The question of whether Ca²⁺ influx is consecutive to cAMP production and/or Ca²⁺ and cAMP are associated with different domains of the ACTH molecule is not yet resolved. Indeed, there are arguments supporting the view that ACTH(1–10) can stimulate steroid secretion through Ca²⁺, without detectable changes in cAMP, whereas ACTH(5–24) or forskolin increases cAMP, and when used together, the two fragments reproduce the effects of ACTH(1–24) (Li *et al.* 1989). ACTH does not induce a rapid and transient Ca²⁺ influx (such as Ang II, which acts through phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P₂), but instead induce a slow, but sustained, Ca²⁺ influx. The latter is mainly mediated by PKA-dependent phosphorylation of L-type Ca²⁺ channels (Tremblay *et al.* 1991), as stimulation of aldosterone by ACTH is completely inhibited by verapamil, an L-type Ca²⁺ channel blocker (Kojima *et al.* 1985b, Gallo-Payet *et al.* 1996) (Hattangady *et al.* 2012, Gallo-Payet & Battista 2014). Some studies have shown that rat ZG cells are much more sensitive to extracellular Ca²⁺ than ZF cells (Schiebinger *et al.* 1985). However, in bovine adrenal glands, sensitivities to Ca²⁺ of ZF cells and ZG cells are similar. Specifically, ACTH and O-nitrophenyl sulfenyl-ACTH (NPS-ACTH) (an analog of ACTH that does not increase cAMP) increase intracellular Ca²⁺ and stimulate cortisol synthesis by bovine ZF cells at concentrations

that produce little or no increase in cAMP synthesis (Liu *et al.* 2010).

At least in ZG cells, Ca^{2+} acts on almost all steps of steroidogenesis: Gs activation of AC, cholesterol ester hydrolase activity, activation of intramitochondrial cholesterol transfer, and expression of StAR and most steroidogenic enzymes (Cherradi *et al.* 1998). The role of calcium/calmodulin-dependent protein kinase (Ca^{2+} -CaMK) in adrenal aldosterone production has recently been confirmed, using both pharmacological and molecular approaches (Nanba *et al.* 2015). Nishimoto and coworkers (Nishimoto *et al.* 2012, 2013) have compared the transcriptional profiles of ZG and ZF in rats. Although similarities between early ACTH events in ZG and ZF were detected, important differences were identified. With the exception of *Cyp11b2* and the gene encoding Ang II receptor type 1, these authors identified genes encoding extracellular matrix proteins, Ca^{2+} and K^{+} channels, as well as transforming growth factor beta (TGF- β), and members of the WNT/ β -catenin and ACTH signaling pathways (Nishimoto *et al.* 2013).

Mechanisms regulating cAMP production and Ca^{2+} influx

Cyclic AMP levels and Ca^{2+} influx are regulated by multiple and sophisticated mechanisms. In particular, the intracellular concentration of cAMP is partly determined by (1) a balance between AC activation through the GTP-binding protein Gs and inhibition through the GTP-binding inhibitory protein Gi (Hausdorff *et al.* 1987, Begeot *et al.* 1988, Hausdorff *et al.* 1989); and (2) several isoforms of ACs (AC5/6, insensitive to Ca^{2+} , AC3, activated by Ca^{2+} , and AC4, activated by the $\beta\gamma$ subunits of G proteins) (Shen *et al.* 1997, Côté *et al.* 2001). Studies of gene expression of the rat ZG indeed showed that AC3 and AC4 are selectively enriched in ZG (Nishimoto *et al.* 2013); (3) several isoforms of phosphodiesterases (PDEs), in particular cGMP-PDE2 (the highest concentrations being found in the ZG (McFarlane & Sowers 2003)) and PDE8, important in regulating corticosterone secretion in ZF cells (Tsai & Beavo 2011).

Effects of ACTH on electrical properties of adrenocortical cells

Adrenocortical cells are characterized by a very negative resting membrane potential ranging from -78 to -90 mV (thus similar to that found in excitable cells) and by

the presence of several channels, including (1) voltage-dependent K^{+} and Ca^{2+} channels; (2) two types of Ca^{2+} channels: the T-type or low-voltage-activated channels (referred to as $\text{Ca}_v3.x$ after the channels were cloned) and the L-type channels or high-voltage-activated channels ($\text{Ca}_v1.x$); (3) voltage-independent Ca^{2+} channels; and (4) background channels (such as TASK and TREK channels) (the 'tandem of P domains in a weak inwardly rectifying K^{+} channel'). In addition, as excitable cells, adrenocortical cells are able to generate spontaneous action potentials (Matthews & Saffran 1973, Lymangrover 1980, Tabares & Lopez-Barneo 1986, Enyeart 2005, Guagliardo *et al.* 2012, Gallo-Payet & Battista 2014).

An important difference between ZG and ZF cells is their sensitivity toward K^{+} ions (which are involved in cell depolarization, and therefore Ca^{2+} influx) and thus higher impact on aldosterone secretion, compared with corticosterone/cortisol secretion in ZF cells (Enyeart 2005, Guagliardo *et al.* 2012, Gallo-Payet & Battista 2014). Such observations could explain that, in humans, aldosterone secretion is more sensitive to low doses of ACTH(1–24) than the secretion of cortisol or DHEA (Daidoh *et al.* 1995), especially in conditions of sodium depletion (Rayfield *et al.* 1973, Kem *et al.* 1975, Nicholls *et al.* 1975). In rat and human ZG cells, binding of ACTH to its receptor induces a rapid membrane depolarization, in part due to blockade of K^{+} channels (Payet *et al.* 1987, 1994). Simultaneously, depolarization transiently abolishes T-channel activity (Durroux *et al.* 1991) and increases the amplitude of the L-type current, through a cAMP-dependent or a PKA-dependent phosphorylation of these L-type channels (Durroux *et al.* 1991).

Early studies conducted in Y1 cells do not support the concept that activation of voltage-dependent Ca^{2+} channels is an important mechanism for steroidogenesis (Coyne *et al.* 1996), as the steroidogenic response to ACTH was observed even in the presence of blockers known to affect both Ca^{2+} and K^{+} channels or in a medium containing low calcium concentration, suggesting that extracellular Ca^{2+} is not critical for a steroidogenic response (Coyne *et al.* 1996). However, subsequent studies performed with ZF cells from bovine origin have shown that ACTH affects the activity of various channels. ACTH inhibits bTREK-1 channels, inducing depolarization, which in turn induces activation of T- and L-type Ca^{2+} channels. Mibefradil, a specific T-channel blocker, inhibits ACTH-induced cortisol secretion in fasciculata cells (Enyeart *et al.* 1993). This mechanism is independent of PKA but can be mimicked

by exchange protein directly activated by cAMP (Epac)-specific cAMP analogs (Liu *et al.* 2008). Epacs also enhance the expression of both Cav3.2 and functional Ca^{2+} channels (Liu *et al.* 2010). The contribution of Ca^{2+} to genome-wide actions of ACTH has been explored in Y1 cells (Schimmer *et al.* 2007). Cells were treated with the Ca^{2+} ionophore A23187 (10 μM) for 24 h to promote Ca^{2+} influx and changes in transcript accumulation were profiled using the 1.7 K human cDNA array. One hundred and twenty nine transcripts were up-regulated and 127 were down-regulated by this treatment, and 45 of these matched transcripts were regulated by ACTH. Interestingly, most of the ACTH-regulated transcripts assigned to the Ca^{2+} signaling pathway by these criteria also fulfilled criteria for activation *via* the cAMP pathway (Schimmer *et al.* 2007), further indicating that Ca^{2+} and cAMP are not independent, but closely interconnected.

Secondary intracellular events and implication of extracellular matrix (ECM) and cytoskeleton

Although cAMP-PKA- Ca^{2+} mediates most of the effects of ACTH, a number of PKA-independent effects of cAMP, including involvement of the exchange protein, were directly activated by cAMP (Epac1/2) (Liu *et al.* 2010). Moreover, the observations that ACTH and/or cAMP induced morphological changes of adrenal cells from flat and adherent to round and loosely attached prompted many investigators to investigate how the cytoskeleton (in particular through reorganization of the actin filament network and its associated proteins) was implicated in ACTH responses (Feuillolley & Vaudry 1996, Côté *et al.* 1997, Hall & Almahbobi 1997, Sewer & Li 2008).

Over the years, some of these non-canonical pathways have been well documented. For example, it has been known for decades that ACTH stimulates arachidonic acid (AA) release through a cAMP- and PKA-dependent mechanism and its lipoxygenase products (Hirai *et al.* 1985) are part of a complex of proteins that participate in the activation of StAR (Kang *et al.* 1997, Wang *et al.* 2003), but also in the transport of cholesterol into mitochondria (Cooke *et al.* 2011). Breakdown of phosphatidylinositol 4,5-bisphosphate ($\text{PtdIns}(4,5)\text{P}_2$) has been reported, both in bovine ZF cells (Bird *et al.* 1990) and in rat ZG cells (Gallo-Payet & Payet 1989). However, the production of inositol trisphosphate induced by ACTH is not sufficient to release Ca^{2+} from intracellular stores, thus suggesting that diacylglycerol (the other second messenger resulting from $\text{PtdIns}(4,5)\text{P}_2$ breakdown) and subsequent PKC activation may have a role in ACTH-induced steroid

secretion (Cozza *et al.* 1990) or in the functional zonation of the adrenal cortex. It has been shown that PKC-induced activin A suppresses ACTH stimulation of CYP17A1 in the ZG to favor steroidogenesis toward aldosterone secretion, thereby contributing to functional adrenocortical zonation (Hofland *et al.* 2013).

The contribution of cell-matrix interactions to intracellular events leading to steroidogenesis is now well documented (Cheng & Hornsby 1992), in which fibronectin and collagens favor steroid synthesis and laminin favors cell proliferation (Otis *et al.* 2007), chemotaxis, and haptotaxis (Feige *et al.* 1998). Binding of ECM components to their receptors, integrins, favors tyrosine phosphorylation of several focal adhesion proteins that facilitate spreading of cells on their substratum, in particular on fibronectin and collagens. The rounding up of the cells following ACTH stimulation is correlated with both a loss of focal adhesions and a specific decrease in paxillin phosphorylation. This latter effect is mediated by the phosphotyrosine phosphatase, SHP-2 (Rocchi *et al.* 2000), itself activated by PKA-dependent serine phosphorylation. This last step has been reported to be essential for cAMP-induced corticosterone secretion (Sewer & Li 2008, Cooke *et al.* 2011, Gallo-Payet & Battista 2014). Li and Sewer (2010) showed that these cytoskeleton-associated modifications may dictate the nature of the steroid production. These examples support the view that the morphological and functional responses to PKA activation in steroidogenic cells are closely related to cytoskeleton dynamics in interaction with ECM and integrins (illustrated in Fig. 2).

Involvement of MAPK pathways Initial studies performed with bovine and rat adrenocortical cells have shown that ACTH does not stimulate $\text{p44/p42}^{\text{mapk}}$ activity under conditions in which Ang II is effective (Chabre *et al.* 1995, Gallo-Payet *et al.* 1999), although *in vivo* ACTH increases ERK1 (p44^{mapk}), but not ERK2 (p42^{mapk}) in ZG, but not in the inner zones (McNeill *et al.* 2005). In Y1 adrenocortical cells (Lotfi *et al.* 1997, Le & Schimmer 2001), NCI-H295R cells (Janes *et al.* 2008), and more recently MC2R-transfected cells (Sebag & Hinkle 2010, Roy *et al.* 2011), ACTH induces a rapid increase in $\text{p44/p42}^{\text{mapk}}$ phosphorylation while also promoting a lower but sustained and concentration-dependent p38 MAPK phosphorylation. The c-Jun N-terminal kinases pathway, however, was not stimulated under the same conditions. Examination of the mechanism involved indicates that cAMP participates in, but does not reproduce, $\text{p44/p42}^{\text{mapk}}$ activation by ACTH (Roy *et al.* 2011), as ACTH is more

Figure 2

Involvement of the extracellular matrix (ECM) and the cytoskeleton in ACTH-stimulated rat adrenal glomerulosa cells. (A) Immunofluorescence labeling of actin filaments and paxillin of rat glomerulosa cells, incubated without (Control) or with 10 nM ACTH for 5 min. Cells were processed for immunofluorescence labeling, using phalloidin coupled to Alexa-Fluor 594 nm for visualization of F-actin (red) and with anti-paxillin antibody coupled to Alexa-Fluor 488 nm for visualization of paxillin (green). Merged images are illustrated. Scale bars, 13 μ m. (B) Illustration of signaling pathways linked to ECM and cytoskeleton. In control conditions, binding of fibronectin or collagen to their integrins promotes strong cell adhesion, evidenced by the flat polygonal morphology, the thin stress fibers across the entire cell and by the presence of focal adhesion points revealed by paxillin labeling, as illustrated by the green fluorescent dots in the left part of panel A. ACTH induces a rapid but transient formation of a dense F-actin ring at the cell membrane, with disruption of the stress fiber network, as illustrated in the right part of panel A. These changes are accompanied by a dephosphorylation of paxillin at the plasma membrane and by the activation of the actin-associated kinases, such as the phosphotyrosine phosphatase, SHP2, which increase cell functionality.

efficient in increasing p44/p42^{mapk} phosphorylation than forskolin or cAMP analogs. Phosphorylated p44/p42^{mapk} was observed in the cytoplasm rather than in the nucleus, supporting the view that localization of p44/p42^{mapk} in the cytoplasm may be associated with cellular differentiation, such as steroid biosynthesis or hypertrophy or (Poderoso *et al.* 2008).

Other ECM components which affect cell morphology and function In addition to the proteins mentioned above, other ECM components affect cell morphology and function. Among these are ephrins (EphA) and their receptors, which are mainly present in the ZG. Interestingly, the level of expression of EphA2 closely correlates with changes in the ZG phenotype, in particular it is increased in animals

on a low-sodium diet (which increases ZG size), but decreased by ACTH treatment (which increases ZF size) (Brennan *et al.* 2008). Another family of extracellular matrix proteins, thrombospondins, is expressed in bovine adrenal glands, with thrombospondin 2 (TSP2) promoting cell attachment but preventing spreading of adrenocortical cells in primary culture (Feige *et al.* 1998).

Gap junction channels These channels facilitate direct exchange between adjacent cells, thus enabling propagation of signaling throughout neighboring cells. *In vivo* and *in vitro* studies have shown a strong positive correlation between ACTH-increased steroidogenesis of the adrenal glands and the expression of connexin 43 (α 1Cx43), the main component of gap junctions in the

adrenal cortex. However, there is an inverse correlation between Cx43 expression and cell proliferation in human adrenocortical tumors (Murray et al. 2003).

Adrenocortical pathologies associated with defective signaling pathways

Although mutations in genes encoding steroidogenic enzymes have long been described as the main cause of adrenal cortex pathologies, more recent molecular studies have shown that several intracellular mediators of ACTH action may also have an important impact on these pathologies, in particular in cortisol-producing adrenocortical tumors. For example, McCune–Albright syndrome is caused by mutations in the gene encoding the α -subunits of G proteins (*GNAS*); in Carney complex and in adrenocortical adenomas, inactivating mutations in the *PRKARIA* gene (encoding the $R\alpha$ subunit of PKA) lead to micronodular hyperplasias including a pigmented form referred to as primary pigmented nodular adrenocortical disease (PPNAD) (de Jossineau et al. 2012, Berthon et al. 2015, Lacroix et al. 2015); mutations in *PDE8B* and *PDE11A* have been found in adrenal hyperplasia, Cushing's syndrome, or in polycystic ovary syndrome (PCOS) (Horvath et al. 2006, Tsai & Beavo 2011, Leal et al. 2015). Decreased expression of cAMP-regulated aldose reductase (*AKR1B1*) is associated with malignancy in human sporadic adrenocortical tumors (Lefrançois-Martinez et al. 2004), or mutations in the components of the Wnt pathway are frequently found in adrenocortical tumors and carcinomas where β -catenin accumulates in the nucleus (El Wakil & Lalli 2011, Berthon et al. 2012).

FGD, characterized by the failure of the adrenal cortex to produce GC, was first shown to be caused by loss-of-function mutations in *MC2R*. After the discovery of the causative role of *MRAP1* in FDG, more recent studies also identified another protein from the same family, *MRAP2*, which seems to be linked to obesity (Meimaridou et al. 2013, Jackson et al. 2015). Finally, it is important to consider extra-pituitary production of ACTH. In particular, recent studies indicate that cortisol secretion by adrenal glands in patients with macronodular hyperplasia and Cushing's syndrome is regulated by ACTH produced in hyperplastic adrenal glands by a subpopulation of steroidogenic cells (Louiset et al. 2013). Following this discovery that the hypercortisolism associated with bilateral macronodular adrenal hyperplasia appears to be ACTH-dependent, 'ACTH-independent macronodular adrenocortical hyperplasia (AIMAH)' has been renamed as 'primary macronodular hyperplasia (PMAH)' (Louiset et al. 2013).

From genomics to physiopathology

Recent studies have shown dysregulated microRNA (miRNA) expressions in adrenocortical tumors. In particular, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found to be overexpressed, whereas miR-195, miR-497, and miR-1974 were found to be underexpressed in adrenocortical cancers (Ozata et al. 2011, Chabre et al. 2013). These dysregulated miRNAs are detectable in serum samples and may be candidate serum biomarkers for distinguishing between benign and malignant adrenocortical tumors (Patel et al. 2013).

Gene expression profiling of human adrenocortical tumors using cDNA microarrays have identified several candidate genes as markers of malignancy (de Fraipont et al. 2005). For example, PA represents the most common cause of secondary hypertension, characterized by dysregulation of aldosterone production (Cao et al. 2012, Monticone et al. 2012). The expression of aldosterone synthase (*CYP11B2*), *MC2R*, and their regulating transcription factors are increased in adrenal incidentaloma (AI)-hypertensive patients compared with normotensive patients and thus may be used to distinguish subclinical or atypical primary aldosteronism (PA) from AIs (Cao et al. 2012).

Recent information also connects PA and channel deficiencies (channelopathies). Two background K^+ channels have been associated with PA in rodents and humans: *KCNK3* (*TASK1*) and *KCNK9* (*TASK3*), one G-protein-activated inward rectifier K^+ channel 4 (*GIRK4*, encoded by the *KCNJ5* gene) and the voltage-dependent T-type Ca^{2+} channel (*CaV3.2*) (Chen et al. 2015). *TASK1* affects cell differentiation and prevents expression of aldosterone synthase in the ZF, whereas *TASK3* controls aldosterone secretion in ZG cells (Bandulik et al. 2014). Mice with single deletions of the *Task1* or *Task3* gene as well as *Task1/Task3* double knockout mice display partially autonomous aldosterone synthesis. These deletions also have a profound impact on adrenal zonation (Davies et al. 2008, Heitzmann et al. 2008). Indeed, deletion of *Task1* changed adrenal zonation and expression of *CYP11B2*, which was absent in the outermost ZG but was expressed to a large extent in the ZF. Furthermore, this expression pattern seemed to be restricted to females and to males before puberty. TASK channels maintain the membrane potential of ZG cells at a polarized ~ 70 mV by being constitutively open and acting as a K^+ leak channel. Decreased expression of *TASK2* is also associated with a higher expression of miR-23 and miR-34, steroidogenic

acute regulatory protein, and CYP11B2, thus enhancing aldosterone production (Lenzini *et al.* 2014).

Besides TASK channels, mutations occurring near the selectivity filter of the inward rectifying K⁺ channel *KCNJ5* (Kir3.4) also result in PA (Choi *et al.* 2011). *KCNJ5* mutations are prevalent in sporadic APAs. These mutations interfere with the selectivity filter of GIRK4 causing Na⁺ entry, cell depolarization, and Ca²⁺ channel opening, resulting in constitutive aldosterone production (Mulatero *et al.* 2013). Voltage-gated Ca²⁺ channels are also implicated in PA (Felizola *et al.* 2014). Indeed, calcium channel blockers can be efficiently used in the treatment of PA-related hypertension. The α -subunits of L-, N-, and T-type calcium channels have been analyzed in 74 adrenocortical aldosterone-producing adenomas (APAs) and 16 cortisol-producing adenomas using quantitative RT-PCR. Among these channel subunits, only CaV3.2 mRNA levels were significantly correlated with plasma aldosterone levels, CYP11B2 expression levels, and the presence of *KCNJ5* mutations in APA, suggesting that they are involved in Ca²⁺-related aldosterone biosynthesis (Felizola *et al.* 2014).

Figure 3

Overview of the main signaling modules implicated in the effect of ACTH on adrenocortical cells. Regulation of ACTH action on adrenocortical cells may occur at different levels that can be divided into modules: Module 1, ACTH binding to its receptor, MC2R; Module 2, production of second messengers; Module 3, modulation of membrane channels; Module 4, implication of the extracellular matrix and cytoskeleton; Module 5, activation of various kinases and phosphatases; and finally Module 6, proteins and enzymes engaged in steroidogenesis or trophic action. Each of these modules could be considered as independent signaling cascades that interact through some of their elements, as illustrated in Fig. 4.

Conclusion of ACTH and adrenal function

Although cAMP is still considered to be the main second messenger of ACTH action, and PKA the most important kinase stimulated by ACTH, each of the other ACTH effectors mentioned in this review are equally important modulators of ACTH response, as part of complex intracellular signaling platforms. The mechanism of action and regulation of StAR is an example of this complexity. StAR acts through a protein complex, the 'transducesome' comprising, in addition to the TSPO, a voltage-dependent anion channel, a TSPO-associated protein 7 (PAP7), and protein kinase A regulatory subunit 1 α (PKAR1A) (Miller & Auchus 2011, Manna *et al.* 2009, Rone *et al.* 2009). All pathways implicated in steroidogenesis and adrenal growth are closely interconnected and probably dependent on the extracellular matrix and the cytoskeleton (for a summary, see Fig. 3 and 4). For example, cell environment is important to dictate the nature of steroids secreted (cortisol vs DHEA) and even the activation of transcription factors (e.g., Dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X-chromosome, gene 1 (DAX1)) (Chamoux *et al.* 2002, Battista *et al.* 2005, Otis *et al.* 2007, Li & Sewer 2010). ACTH loses its protective effects when the adrenal architecture is disrupted (Carsia *et al.* 1997). The precise mechanisms of interactions between the ECM and integrin receptors with the cytoskeleton and intracellular kinases is beginning to emerge but is yet to be correlated with *in vivo* physiology.

Extra-adrenal actions of ACTH

Evidence for the presence of MC2R in tissues other than the adrenal cortex begins to emerge. In many instances, MC2R has the same properties in other tissues as in the adrenal cortex, namely acting as a differentiating factor and using the same main signaling pathways. Some examples of ACTH action in tissues other than the adrenal cortex are given below.

ACTH and adipocyte functionality

The demonstration of the presence of both MC2R (ACTH receptor) and MC5R (α -MSH receptor), in murine 3T3-L1 cells differentiated into adipocytes (Cammis *et al.* 1995, Noon *et al.* 2004, Moller *et al.* 2011), has confirmed earlier studies showing that ACTH stimulates lipolytic activity in mature adipocytes. Indeed, knockdown of *Mc2r* in

Figure 4

Illustrations of the main signaling cascades stimulated by ACTH, from binding to its receptor to cellular function in adrenocortical cells. (A) ACTH binds to MC2R and through interaction with MRAPs (Module 1) and initiates signaling, by activating Gs and various isoforms of ACs that increase cAMP. MC2R is also linked to G_i protein; activation of α_i decreases the level of cAMP, whereas the release of βγ-subunits stimulates other effectors such as Mitogen-activated protein kinases (MAPK) cascade or cationic Cl⁻ channels (Module 2). Binding of cAMP to the regulatory subunits of protein kinase A results in the phosphorylation of several proteins, including steroidogenic acute regulatory protein (StAR) and the hormone-sensitive lipase. Protein kinase A (PKA) also regulates the level of expression of the receptors implicated in the uptake of cholesterol and genes encoding the steroidogenic enzymes (Module 5). The final output of this cascade is steroidogenesis, which is initiated in the mitochondria. cAMP also has a number of PKA-independent effects, including involvement of the exchange protein directly activated by cAMP (Epac1/2). cAMP also regulates its own intracellular level through activation of phosphodiesterases, in particular, PDE2 and PDE8 (Module 5). (B) Simultaneously, ACTH induces depolarization of the cell membrane inducing Ca²⁺ influx (Module 3). PKA also activates Ca²⁺ influx through L-type channels. The subsequent increase in intracellular calcium (Cai) activates Ca²⁺-CaMK and steroidogenesis (Module 6). (C) Activated MC2R also interact with ECM and cytoskeleton-associated proteins (Module 4), modulating the phosphorylation and activation of a number of proteins that are involved in functional integrity of the cells. A decrease in paxillin phosphorylation and activation of the phosphotyrosine phosphatase, SHP2, itself activated by PKA-dependent serine phosphorylation is responsible for the rapid effect of ACTH on the rounding-up of adrenocortical cells in culture. SHP2 also induces dephosphorylation of specific substrate(s), including some involved directly or indirectly in steroidogenesis, such as the acyl-CoA synthetase (ACS4), which sequesters AA as arachidonyl-CoA (AA-CoA) (Module 5), hence participating in StAR activation and initiation of steroidogenesis (Module 6). Cytoskeleton-associated proteins and/or PKA are also implicated in the activation of the MAPK signaling, necessary to promote the trophic action of ACTH (Module 5). Clearly identified pathogenic mutations of key proteins are indicated in red. Among these mutations are loss of function of MC2R or MRAPs, activating mutations of the *GNAS* gene (encoding Gsα subunit), inactivating mutations of genes encoding the regulatory subunit of PKA (Ria) (*PRKAR1A*), encoding phosphodiesterases (*PDE11A* and *PDE8B*) or Aldo-keto-reductases (*AKR1B1*). Some mutations in voltage-dependent K⁺ channels are directly involved in primary aldosteronism, in particular mutations of the *KCNJ5* gene encoding the potassium channel Kir3.4 (also called G-protein-activated inward rectifier potassium channel 4, GIRK4), and of the two genes *KCNQ1* and *KCNE1*, encoding the pore- and regulatory subunits of the slowly activating delayed K⁺ current, I_{ks}. The resulting sustained Ca²⁺ influx increases activation of CYP11B2 and thus sustained increase in aldosterone secretion. Finally, the temporal integration of these signaling pathways may be coordinated at the levels of signaling microdomains, for example, through A kinase-anchoring proteins, or AKAPs (not illustrated).

3T3-L1 cells reduces lipid content and inhibits expression of differentiation regulators such as peroxisome proliferator-activated receptor (PPAR γ 2) (Noon *et al.* 2004, Betz *et al.* 2012). ACTH and α -MSH are also potent inhibitors of leptin expression (Norman *et al.* 2003). Studies from Iwen and coworkers (Iwen *et al.* 2008) indicate that chronic stimulation of white adipocytes with high doses of ACTH decreases insulin-induced glucose uptake as well as the expression of visfatin and adiponectin genes, whereas the pro-inflammatory cytokine, interleukin-6 (IL-6), and monocyte chemoattractant protein-1 mRNA levels are acutely up-regulated. Thus, ACTH could lead to dysregulation of energy balance, insulin resistance, and cardiometabolic complications when the pituitary–adrenal axis HPA is dysregulated or is under chronic inflammation (Iwen *et al.* 2008).

The role of melanocortins in the physiology of human adipocytes is yet to be fully elucidated. In *ex vivo* experiments with human adipocytes from obese subjects, high expression levels of MC1R, but only low levels of MC2R, have been detected (Smith *et al.* 2003). Nevertheless, MC2R is expressed in human mesenchymal cells (MSC) during adipogenic induction (Smith *et al.* 2003), suggesting that MC2R may have a role as a differentiating factor as in 3T3-L1 cells, but not in fully differentiated cells (Smith *et al.* 2003, Betz *et al.* 2012).

ACTH and matrix synthesis in mesenchymal cells

The expression of MCR in mesenchymal progenitor cell populations is also well documented (Evans *et al.* 2013). In particular, MC2R and MRAP are expressed in human and murine osteoblast cell lines, where they can play a role in differentiation through production of vascular endothelial growth factor (VEGF) (Zaidi *et al.* 2010). In murine osteoblasts, ACTH appears to be a regulator of bone mass, enhancing collagen production (Isales *et al.* 2010, Zaidi *et al.* 2010), an effect occurring in a dose-dependent manner through a transient increase in intracellular Ca²⁺. Neither γ ₂-MSH, a potent MC3R agonist, nor α -MSH, a potent MC5R agonist, duplicates the effects of ACTH, indicating the specificity of ACTH-MC2R action. Mouse aorta-derived mesenchymal progenitor cells also express both MC2R and MC3R. These progenitors respond to ACTH by increasing collagen matrix synthesis and intracellular Ca²⁺ and suggest a role in the maintenance and repair of the vascular extracellular matrix (Evans *et al.* 2013). The same study indicates that both macrophages and

mesenchymal cells are relevant sources of local POMC peptides.

ACTH and thymus growth

ACTH directly controls thymic growth through MC2R, which is expressed in thymic epithelium. Adrenalectomized mice treated with ACTH under conditions repressing endogenous ACTH secretion exhibit an increase in the number of thymocytes and splenic naive T-cells compared with control animals. These results show that ACTH directly controls thymocyte homeostasis independently of circulating GC (Talaber *et al.* 2015).

Involvement in the skin In the skin, mRNA for MC2R and mRNAs for three obligatory enzymes of steroid synthesis, cytochromes P450_{scc}, P450_{c17}, and P450_{c21}, have been detected in normal and pathological human samples (Slominski *et al.* 1996b). In fact, all components of the pituitary–adrenal axis have been detected in the skin, suggesting a role in regulating immune system or hair growth. However, this remains to be better explored for ACTH–MC2R complex, as these latter actions are best known to be mediated by α -MSH peptide (Schauer *et al.* 1994, Slominski *et al.* 1996a).

In mouse testis In fetal/neonatal mouse testis, the ACTH–MC2R complex is localized in Leydig cells, in which it stimulates androgen production. The mechanisms of action involve not only cAMP-PKA, but also AA (*via* phospholipase A2) and p44/p42^{mapk} activation of StAR (Johnston *et al.* 2007).

In prostate cells In the prostate cell lines, LNCaP, PC3, and DU-145 cells, ACTH, through MC2R-induced cAMP, promotes concentration-dependent cell proliferation, suggesting that MC2R is involved in prostate carcinogenesis and that targeting MC2R signaling may provide a novel avenue in prostate carcinoma treatment (Hafiz *et al.* 2012).

ACTH also has a renoprotective effect in chronic kidney disease

In a rat model of tumor necrosis factor (TNF)-induced acute kidney injury, Si *et al.* (2013) found that ACTH gel prevented kidney injury, corrected acute renal dysfunction, and improved survival. Morphologically, ACTH gel ameliorated TNF-induced acute tubular necrosis, associated with a reduction in tubular apoptosis.

ACTH and brain function

The idea that the adrenal cortex through corticosteroids may have a role in mood has been recently reviewed (Vinson & Brennan 2013). Indeed, changes in mood are a common consequence of chronic corticosteroid therapy. Corticosteroids are known for their capacity to generate both euphoria and depression in humans, even if these effects are still poorly understood. It is also known that ACTH/MSH neuropeptides affect social behavior, interact with opiate binding sites, and possess antiepileptic properties. ACTH/MSH peptides also possess neurotropic activities, stimulating regeneration of damaged nerve cells (de Wied 1990, Vinson & Brennan 2013).

Taken together, the data summarized above suggest that the ACTH-MC2R complex is involved in cell differentiation, not only in adipocytes, but also in a variety of tissues, from mesenchymal cell populations to adipocytes as well as in steroidogenesis in skin, testis, and prostate. Furthermore, a high level of ACTH or increased expression of MC2R could contribute to HPA, or to metabolic-related pathologies.

Conclusion: challenges and perspectives

As we have shown in this review, signaling pathways (i.e. second messengers and subsequent intracellular events) in interaction with ECM and integrins control cell fate decisions that ultimately determine the behavior of adrenocortical cells toward steroidogenesis, growth, and eventually aberrant physiology and pathological consequences (see summary in Fig. 3 and 4). Some of the examples given in this review indicate that the time-dependent production of these intracellular mediators may be important to consider in the final cell response. Yet, a transient vs a sustained production of cAMP or MAPK activation does not elicit the same final response. Furthermore, in addition to the well-described signaling cascades illustrated in Fig. 4, some other signaling pathways would deserve further exploration; in particular interaction of second messengers with the scaffold proteins, A kinase-anchoring proteins (AKAPs). AKAPs can target many signaling proteins to specific locations within the cell, creating preferential interactions on the scaffold. For example, AKAP79/150 can associate with K⁺ voltage-dependent channels, ACs, or L-type Ca²⁺ channels. AKAPs can increase the rate at which signal transduction occurs or increase the magnitude of the signal response (Dessauer 2009, Greenwald & Saucerman 2011).

Computational models have been recently developed for the integration of quantitative data from complex systems that could be used as platforms to investigate the dynamic biochemical properties of cells. Studying the dynamics of pathway activity may provide prognostically relevant information different from the information provided by other types of biomarkers, due to their static nature (Hughey *et al.* 2010). Therefore, due to the complexity of the various interacting pathways involved in the regulation of adrenocortical functions (Figs 3 and 4), it would be interesting to develop similar models to explore the potential involvement of these pathways in specific adrenocortical pathologies. For example, alterations in one step could induce a switch activation from one function to another, resulting in the loss or gain of a physiological function, and thus in pathological situations (Lefrançois-Martinez *et al.* 2004, Horvath *et al.* 2006, Tsai & Beavo 2011, de Joussineau *et al.* 2012, Leal *et al.* 2015). The integration of various technologies (such as transcriptomics, proteomics, or metabolomics) combined with computational and mathematical models could be used to identify new therapeutic agents, drug targets, and novel biomarkers, as demonstrated for other paradigms in several recent publications (de Fraipont *et al.* 2005, Choi *et al.* 2011, Patel *et al.* 2013, Lenzini *et al.* 2014, Resendis-Antonio *et al.* 2015).

Declaration of interest

The author declares that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

Work in our laboratory was supported by grants from the Canadian Institutes of Health Research (MOP-10998) and the Canada Research Chairs Program to Nicole Gallo-Payet.

Acknowledgments

The authors would like to thank past students and post-doctoral fellows who have contributed to the work summarized in this review, in particular Marie-Claude Battista, Mylène Côté, Thierry Durroux, Mélissa Otis, and Simon Roy. They are also grateful to Dr Marcel D Payet (Department of Physiology and Biophysics, Faculty of Medicine and Health Sciences, Université de Sherbrooke) for invaluable fruitful collaborations and stimulating discussions throughout the past 30 years and to Dr Jean-Marc Gallo (Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London) for helpful discussions and critical review of the manuscript. Due to space constraints, we have mainly cited reviews, in which original references can be found. The authors also apologize to their colleagues who could not be cited.

References

- Aguilera G, Fujita K & Catt KJ 1981 Mechanisms of inhibition of aldosterone secretion by adrenocorticotropin. *Endocrinology* **108** 522–528.
- Aiba M & Fujibayashi M 2011 Alteration of subcapsular adrenocortical zonation in humans with aging: the progenitor zone predominates over the previously well-developed zona glomerulosa after 40 years of age. *Journal of Histochemistry & Cytochemistry* **59** 557–564. (doi:10.1369/0022155411404071)
- Arlt W & Stewart PM 2005 Adrenal corticosteroid biosynthesis, metabolism, and action. *Endocrinology and Metabolism Clinics of North America* **34** 293–313. (doi:10.1016/j.ecl.2005.01.002)
- Armato U, Nussdorfer GG, Andreis PG, Mazzochi G & Draghi E 1974 Primary tissue culture of human adult adrenocortical cells. Methodology and electron microscopic observations on ACTH-deprived and ACTH-treated cortical cells. *Cell and Tissue Research* **155** 155–180.
- Baig AH, Swords FM, Noon LA, King PJ, Hunyady L & Clark AJ 2001 Desensitization of the Y1 cell adrenocorticotropin receptor: evidence for a restricted heterologous mechanism implying a role for receptor-effector complexes. *Journal of Biological Chemistry* **276** 44792–44797.
- Bandulik S, Tauber P, Lalli E, Barhanin J & Warth R 2014 Two-pore domain potassium channels in the adrenal cortex. *Pflügers Archiv* **467** 1027–1042. (doi:10.1007/s00424-014-1628-6)
- Bassett JR & West SH 1997 Vascularization of the adrenal cortex: its possible involvement in the regulation of steroid hormone release. *Microscopy Research and Technique* **36** 546–557. (doi:10.1002/(SICI)1097-0029(19970315)36:6<546::AID-JEMT11>3.0.CO;2-O)
- Battista MC, Otis M, Cote M, Laforest A, Peter M, Lalli E & Gallo-Payet N 2005 Extracellular matrix and hormones modulate DAX-1 localization in the human fetal adrenal gland. *Journal of Clinical Endocrinology & Metabolism* **90** 5426–5431. (doi:10.1210/jc.2005-0666)
- Battista MC, Roberge C, Martinez A & Gallo-Payet N 2009 24-dehydrocholesterol reductase/seladin-1: a key protein differentially involved in adrenocorticotropin effects observed in human and rat adrenal cortex. *Endocrinology* **150** 4180–4190. (doi:10.1210/en.2009-0410)
- Begeot M, Langlois D, Penhoat A & Saez JM 1988 Variations in guanine-binding proteins (Gs, Gi) in cultured bovine adrenal cells. Consequences on the effects of phorbol ester and angiotensin II on adrenocorticotropin-induced and cholera-toxin-induced cAMP production. *European Journal of Biochemistry* **174** 317–321.
- Berthon A, Martinez A, Bertherat J & Val P 2012 Wnt/beta-catenin signalling in adrenal physiology and tumour development. *Molecular and Cellular Endocrinology* **351** 87–95. (doi:10.1016/j.mce.2011.09.009)
- Berthon AS, Szarek E & Stratakis CA 2015 PRKACA: the catalytic subunit of protein kinase A and adrenocortical tumors. *Frontiers in Cell and Developmental Biology* **3** 26. (doi:10.3389/fcell.2015.00026)
- Betz MJ, Hatiboglu N, Mauracher B, Hadaschik D, Sauter A, Demmelmaier H, Koletzko B, Beuschlein F & Slawik M 2012 Mc2 receptor knockdown modulates differentiation and lipid composition in adipocytes. *Hormone and Metabolic Research* **44** 670–675. (doi:10.1055/s-0032-1314854)
- Bicknell AB 2008 The tissue-specific processing of pro-opiomelanocortin. *Journal of Neuroendocrinology* **20** 692–699. (doi:10.1111/j.1365-2826.2008.01709.x)
- Bicknell AB 2016 60 YEARS OF POMC: N-terminal POMC peptides and adrenal growth. *Journal of Molecular Endocrinology* **56** T39–T48. (doi:10.1530/JME-15-0269)
- Bicknell AB, Lomthaisong K, Woods RJ, Hutchinson EG, Bennett HP, Gladwell RT & Lowry PJ 2001 Characterization of a serine protease that cleaves pro-gamma-melanotropin at the adrenal to stimulate growth. *Cell* **105** 903–912.
- Bird IM, Smith AD & Schulster D 1990 Signal transduction in rat adrenal fasciculata cells stimulated by ACTH1-39 and ACTH5-24: role of the phosphoinositide response in steroidogenesis. *Journal of Lipid Mediators* **2** 343–354.
- Bird IM, Pasquarette MM, Rainey WE & Mason JI 1996 Differential control of 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase expression in human adrenocortical H295R cells. *Journal of Clinical Endocrinology & Metabolism* **81** 2171–2178.
- Bornstein SR, Engeland WC, Ehrhart-Bornstein M & Herman JP 2008 Dissociation of ACTH and glucocorticoids. *Trends in Endocrinology & Metabolism* **19** 175–180. (doi:10.1016/j.tem.2008.01.009)
- Brennan CH, Chittka A, Barker S & Vinson GP 2008 Eph receptors and zonation in the rat adrenal cortex. *Journal of Endocrinology* **198** 185–191. (doi:10.1677/JOE-08-0084)
- Briet M & Schiffrin EL 2011 The role of aldosterone in the metabolic syndrome. *Current Hypertension Reports* **13** 163–172. (doi:10.1007/s11906-011-0182-2)
- Cammas FM, Kapas S, Barker S & Clark AJ 1995 Cloning, characterization and expression of a functional mouse ACTH receptor. *Biochemical and Biophysical Research Communications* **212** 912–918.
- Cao CX, Yang XC, Gao YX, Zhuang M, Wang KP, Sun LJ & Wang XS 2012 Expression of aldosterone synthase and adrenocorticotrophic hormone receptor in adrenal incidentalomas from normotensive and hypertensive patients: distinguishing subclinical or atypical primary aldosteronism from adrenal incidentaloma. *International Journal of Molecular Medicine* **30** 1396–1402. (doi:10.3892/ijmm.2012.1144)
- Carsia RV, Tilly KI & Tilly JL 1997 Hormonal modulation of apoptosis in the rat adrenal gland *in vitro* is dependent on structural integrity. *Endocrine* **7** 377–381. (doi:10.1007/BF02801333)
- Cawley NX, Li Z & Loh YP 2016 60 YEARS OF POMC: Biosynthesis, trafficking and secretion of proopiomelanocortin-derived peptides. *Journal of Molecular Endocrinology* **56** T119–T133. (doi:10.1530/JME-15-0323)
- Chabre O, Cornillon F, Bottari S, Chambaz E & Vilgrain I 1995 Hormonal regulation of mitogen-activated protein kinase activity in bovine adrenocortical cells: cross-talk between phosphoinositides, adenosine 3', 5'-monophosphate, and tyrosine kinase receptor pathways. *Endocrinology* **136** 956–964.
- Chabre O, Libe R, Assie G, Barreau O, Bertherat J, Bertagna X, Feige JJ & Cherradi N 2013 Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. *Endocrine-Related Cancer* **20** 579–594. (doi:10.1530/ERC-13-0051)
- Chamoux E, Narcy A, Lehoux JG & Gallo-Payet N 2002 Fibronectin, laminin, and collagen IV as modulators of cell behavior during adrenal gland development in the human fetus. *Journal of Clinical Endocrinology & Metabolism* **87** 1819–1828.
- Chan LE, Metherell LA & Clark AJ 2011 Effects of melanocortins on adrenal gland physiology. *European Journal of Pharmacology* **660** 171–180. (doi:10.1016/j.ejphar.2010.11.041)
- Chen M, Aprahamian CJ, Kesterson RA, Harmon CM & Yang Y 2007 Molecular identification of the human melanocortin-2 receptor responsible for ligand binding and signaling. *Biochemistry* **46** 11389–11397. (doi:10.1021/bi700125e)
- Chen AX, Nishimoto K, Nanba K & Rainey WE 2015 Potassium channels related to primary aldosteronism: expression similarities and differences between human and rat adrenals. *Molecular and Cellular Endocrinology* **417** 141–148. (doi:10.1016/j.mce.2015.09.011)
- Cheng C & Hornsby P 1992 Expression of 11 beta-hydroxylase and 21-hydroxylase in long-term cultures of bovine adrenocortical cells requires extracellular matrix factors. *Endocrinology* **130** 2883–2889.
- Cherradi N, Rossier MF, Vallotton MB & Capponi AM 1996 Calcium stimulates intramitochondrial cholesterol transfer in bovine adrenal glomerulosa cells. *Journal of Biological Chemistry* **271** 25971–25975.

- Cherradi N, Brandenburger Y & Capponi AM 1998 Mitochondrial regulation of mineralocorticoid biosynthesis by calcium and the StAR protein. *European Journal of Endocrinology* **139** 249–256.
- Chida D, Nakagawa S, Nagai S, Sagara H, Katsumata H, Imaki T, Suzuki H, Mitani F, Ogishima T, Shimizu C *et al.* 2007 Melanocortin 2 receptor is required for adrenal gland development, steroidogenesis, and neonatal gluconeogenesis. *PNAS* **104** 18205–18210.
- Chinn AM, Ciais D, Bailly S, Chambaz E, LaMarre J & Feige JJ 2002 Identification of two novel ACTH-responsive genes encoding manganese-dependent superoxide dismutase (SOD2) and the zinc finger protein TIS11b [tetradecanoyl phorbol acetate (TPA)-inducible sequence 11b]. *Molecular Endocrinology* **16** 1417–1427.
- Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ *et al.* 2011 K⁺ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. *Science* **331** 768–772. (doi:10.1126/science.1198785)
- Chung S, Son GH & Kim K 2011 Circadian rhythm of adrenal glucocorticoid: its regulation and clinical implications. *Biochimica et Biophysica Acta* **1812** 581–591. (doi:10.1016/j.bbadis.2011.02.003)
- Clark AJL 2016 60 YEARS OF POMC: The proopiomelanocortin gene: discovery, deletion and disease. *Journal of Molecular Endocrinology* **56** T27–T37. (doi:10.1530/JME-15-0268)
- Coll AP, Challis BG, Yeo GS, Snell K, Piper SJ, Halsall D, Thresher RR & O'Rahilly S 2004 The effects of proopiomelanocortin deficiency on murine adrenal development and responsiveness to adrenocorticotropin. *Endocrinology* **145** 4721–4727.
- Cone RD 2006 Studies on the physiological functions of the melanocortin system. *Endocrine Reviews* **27** 736–749. (doi:10.1210/er.2006-0034)
- Cooke M, Mele P, Maloberti P, Duarte A, Poderoso C, Orlando U, Paz C, Cornejo Maciel F & Podesta EJ 2011 Tyrosine phosphatases as key regulators of StAR induction and cholesterol transport: SHP2 as a potential tyrosine phosphatase involved in steroid synthesis. *Molecular and Cellular Endocrinology* **336** 63–69. (doi:10.1016/j.mce.2010.11.030)
- Cooray SN & Clark AJ 2011 Melanocortin receptors and their accessory proteins. *Molecular and Cellular Endocrinology* **331** 215–221. (doi:10.1016/j.mce.2010.07.015)
- Corander MP & Coll AP 2011 Melanocortins and body weight regulation: glucocorticoids, Agouti-related protein and beyond. *European Journal of Pharmacology* **660** 111–118. (doi:10.1016/j.ejphar.2010.10.103)
- Côté M, Payet M-D & Gallo-Payet N 1997 Association of alpha S-subunit of the GS protein with microfilaments and microtubules: implication during adrenocorticotropin stimulation in rat adrenal glomerulosa cells. *Endocrinology* **138** 69–78.
- Côté M, Guillon G, Payet M & Gallo-Payet N 2001 Expression and regulation of adenylyl cyclase isoforms in the human adrenal gland. *Journal of Clinical Endocrinology & Metabolism* **86** 4495–4503.
- Coyne M, Wang G & Lemos J 1996 Calcium channels do not play a role in the steroid response to ACTH IN Y1 adrenocortical cells. *Endocrine Research* **22** 551–556.
- Cozza EN, Vila MC, Acevedo-Duncan M, Farese RV & Gomez-Sanchez CE 1990 Treatment of primary cultures of calf adrenal glomerulosa cells with adrenocorticotropin (ACTH) and phorbol esters: a comparative study of the effects on aldosterone production and ACTH signaling system. *Endocrinology* **126** 2169–2176.
- Crivello JF & Gill GN 1983 Induction of cultured bovine adrenocortical zona glomerulosa cell 17-hydroxylase activity by ACTH. *Molecular and Cellular Endocrinology* **30** 97–107.
- Daidoh H, Morita H, Mune T, Murayama M, Hanafusa J, Ni H, Shibata H & Yasuda K 1995 Responses of plasma adrenocortical steroids to low dose ACTH in normal subjects. *Clinical Endocrinology* **43** 311–315.
- Dallman MF, la Fleur SE, Pecoraro NC, Gomez F, Houshyar H & Akana SF 2004 Minireview: glucocorticoids – food intake, abdominal obesity, and wealthy nations in 2004. *Endocrinology* **145** 2633–2638.
- Davies LA, Hu C, Guagliardo NA, Sen N, Chen X, Talley EM, Carey RM, Bayliss DA & Barrett PQ 2008 TASK channel deletion in mice causes primary hyperaldosteronism. *PNAS* **105** 2203–2208. (doi:10.1073/pnas.0712000105)
- de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E *et al.* 2005 Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. *Journal of Clinical Endocrinology & Metabolism* **90** 1819–1829. (doi:10.1210/jc.2004-1075)
- de Jossineau C, Sahut-Barnola I, Levy I, Saloustros E, Val P, Stratakis CA & Martinez A 2012 The cAMP pathway and the control of adrenocortical development and growth. *Molecular and Cellular Endocrinology* **351** 28–36. (doi:10.1016/j.mce.2011.10.006)
- de Wied D 1990 Neurotrophic effects of ACTH/MSH neuropeptides. *Acta Neurobiologiae Experimentalis* **50** 353–366.
- Dessauer CW 2009 Adenylyl cyclase – A-kinase anchoring protein complexes: the next dimension in cAMP signaling. *Molecular Pharmacology* **76** 935–941. (doi:10.1124/mol.109.059345)
- Dores RM 2009 Adrenocorticotrophic hormone, melanocyte-stimulating hormone, and the melanocortin receptors: revisiting the work of Robert Schwyzer: a thirty-year retrospective. *Annals of the New York Academy of Sciences* **1163** 93–100. (doi:10.1111/j.1749-6632.2009.04434.x)
- Dores RM, Londraville RL, Prokop J, Davis P, Dewey N & Lesinski N 2014 Molecular evolution of GPCRs: melanocortin/melanocortin receptors. *Journal of Molecular Endocrinology* **52** T29–T42. (doi:10.1530/JME-14-0050)
- Dores RM, Liang L, Davis P, Thomas AL & Petko B 2016 60 YEARS OF POMC: Melanocortin receptors: evolution of ligand selectivity for melanocortin peptides. *Journal of Molecular Endocrinology* **56** T119–T133. (doi:10.1530/JME-15-0292)
- Durroux T, Gallo-Payet N & Payet MD 1991 Effects of adrenocorticotropin on action potential and calcium currents in cultured rat and bovine glomerulosa cells. *Endocrinology* **129** 2139–2147.
- El Wakil A & Lalli E 2011 The Wnt/beta-catenin pathway in adrenocortical development and cancer. *Molecular and Cellular Endocrinology* **332** 32–37. (doi:10.1016/j.mce.2010.11.014)
- Enyeart JJ 2005 Biochemical and Ionic signaling mechanisms for ACTH-stimulated cortisol production. *Vitamins and Hormones* **70** 265–279. (doi:10.1016/S0083-6729(05)70008-X)
- Enyeart JJ, Mlinar B & Enyeart JA 1993 T-type Ca²⁺ channels are required for adrenocorticotropin-stimulated cortisol production by bovine adrenal zona fasciculata cells. *Molecular Endocrinology* **7** 1031–1040.
- Estivariz FE, Iturriza F, McLean C, Hope J & Lowry PJ 1982 Stimulation of adrenal mitogenesis by N-terminal proopiocortin peptides. *Nature* **297** 419–422.
- Evans JF, Fernando A & Ragolia L 2012 Functional melanocortin-2 receptors are expressed by mouse aorta-derived mesenchymal progenitor cells. *Molecular and Cellular Endocrinology* **355** 60–70. (doi:10.1016/j.mce.2012.01.019)
- Evans JF, Rodriguez S & Ragolia L 2013 ACTH promotes chondrogenic nodule formation and induces transient elevations in intracellular calcium in rat bone marrow cell cultures via MC2-R signaling. *Cell and Tissue Research* **352** 413–425. (doi:10.1007/s00441-013-1561-6)
- Fakunding J & Catt K 1980 Dependence of aldosterone stimulation in adrenal glomerulosa cells on calcium uptake: effects of lanthanum and verapamil. *Endocrinology* **107** 1345–1353.

- Fakunding J, Chow R & Catt K 1979 The role of calcium in the stimulation of aldosterone production by adrenocorticotropin, angiotensin II, and potassium in isolated glomerulosa cells. *Endocrinology* **105** 327–333.
- Feige J, Keramidas M & Chambaz E 1998 Hormonally regulated components of the adrenocortical cell environment and the control of adrenal cortex homeostasis. *Hormone and Metabolic Research* **30** 421–425.
- Felizola SJ, Maekawa T, Nakamura Y, Satoh F, Ono Y, Kikuchi K, Aritomi S, Ikeda K, Yoshimura M, Tojo K *et al.* 2014 Voltage-gated calcium channels in the human adrenal and primary aldosteronism. *Journal of Steroid Biochemistry and Molecular Biology* **144 Part B** 410–416. (doi:10.1016/j.jsbmb.2014.08.012)
- Feuillolloy M & Vaudry H 1996 Role of the cytoskeleton in adrenocortical cells. *Endocrine Reviews* **17** 269–288.
- Fleury A, Ducharme L & LeHoux JG 1998 In vivo effects of adrenocorticotrophin on the expression of the hamster steroidogenic acute regulatory protein. *Journal of Molecular Endocrinology* **21** 131–139.
- Funder JW & Reincke M 2010 Aldosterone: a cardiovascular risk factor? *Biochimica et Biophysica Acta* **1802** 1188–1192. (doi:10.1016/j.bbdis.2010.08.005)
- Gallo-Payet N & Battista MC 2014 Steroidogenesis-adrenal cell signal transduction. *Comprehensive Physiology* **4** 889–964. (doi:10.1002/cphy.c130050)
- Gallo-Payet N & Payet MD 1989 Excitation-secretion coupling: involvement of potassium channels in ACTH-stimulated rat adrenocortical cells. *Journal of Endocrinology* **120** 409–421.
- Gallo-Payet N, Grazzini E, Côté M, Bilodeau L, Chorvatova A, Payet MD, Chouinard L & Guillon G 1996 Role of calcium in the mechanism of action of ACTH in human adrenocortical cells. *Journal of Clinical Investigation* **98** 460–466.
- Gallo-Payet N, Cote M, Chorvatova A, Guillon G & Payet MD 1999 Cyclic AMP-independent effects of ACTH on glomerulosa cells of the rat adrenal cortex. *Journal of Steroid Biochemistry and Molecular Biology* **69** 335–342.
- Gorrigan RJ, Guasti L, King P, Clark AJ & Chan LF 2011 Localisation of the melanocortin-2-receptor and its accessory proteins in the developing and adult adrenal gland. *Journal of Molecular Endocrinology* **46** 227–232. (doi:10.1530/JME-11-0011)
- Greenwald EC & Saucerman JJ 2011 Bigger, better, faster: principles and models of AKAP anchoring protein signaling. *Journal of Cardiovascular Pharmacology* **58** 462–469. (doi:10.1097/FJC.0b013e31822001e3)
- Guagliardo NA, Yao J, Hu C & Barrett PQ 2012 Minireview: aldosterone biosynthesis: electrically gated for our protection. *Endocrinology* **153** 3579–3586. (doi:10.1210/en.2012-1339)
- Hafiz S, Dennis JC, Schwartz D, Judd R, Tao YX, Khazal K, Akingbemi B, Mo XL, Abdel-Mageed AB, Morrison E *et al.* 2012 Expression of melanocortin receptors in human prostate cancer cell lines: MC2R activation by ACTH increases prostate cancer cell proliferation. *International Journal of Oncology* **41** 1373–1380. (doi:10.3892/ijo.2012.1574)
- Hall PF & Almahbobi G 1997 Roles of microfilaments and intermediate filaments in adrenal steroidogenesis. *Microscopy Research and Technique* **36** 463–479. (doi:10.1002/(SICI)1097-0029(19970315)36:6<463::AID-JEMT4>3.0.CO;2-J)
- Hattangady NG, Olala LO, Bollag WB & Rainey WE 2012 Acute and chronic regulation of aldosterone production. *Molecular and Cellular Endocrinology* **350** 151–162. (doi:10.1016/j.mce.2011.07.034)
- Hausdorff W, Sekura R, Aguilera G & Catt K 1987 Control of aldosterone production by angiotensin II is mediated by two guanine nucleotide regulatory proteins. *Endocrinology* **120** 1668–1678.
- Hausdorff WP, Aguilera G & Catt KJ 1989 Inhibitory actions of somatostatin on cyclic AMP and aldosterone production in agonist-stimulated adrenal glomerulosa cells. *Cell Signaling* **1** 377–386.
- Heitzmann D, Derand R, Jungbauer S, Bandulik S, Sterner C, Schweda F, El Wakil A, Lalli E, Guy N, Mengual R *et al.* 2008 Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. *EMBO Journal* **27** 179–187. (doi:10.1038/sj.emboj.7601934)
- Hinkle PM & Sebag JA 2009 Structure and function of the melanocortin2 receptor accessory protein (MRAP). *Molecular and Cellular Endocrinology* **300** 25–31.
- Hirai A, Tahara K, Tamura Y, Saito H, Terano T & Yoshida S 1985 Involvement of 5-lipoxygenase metabolites in ACTH-stimulated corticosteroidogenesis in rat adrenal glands. *Prostaglandins* **30** 749–767.
- Hofland J, Delhanty PJ, Steenbergen J, Hofland LJ, van Koetsveld PM, van Nederveen FH, de Herder WW, Feelders RA & de Jong FH 2012 Melanocortin 2 receptor-associated protein (MRAP) and MRAP2 in human adrenocortical tissues: regulation of expression and association with ACTH responsiveness. *Journal of Clinical Endocrinology & Metabolism* **97** E747–E754. (doi:10.1210/jc.2011-2328)
- Hofland J, Steenbergen J, Hofland LJ, van Koetsveld PM, Eijken M, van Nederveen FH, Kazemier G, de Herder WW, Feelders RA & de Jong FH 2013 Protein kinase C-induced activin A switches adrenocortical steroidogenesis to aldosterone by suppressing CYP17A1 expression. *American Journal of Physiology: Endocrinology and Metabolism* **305** E736–E744. (doi:10.1152/ajpendo.00034.2013)
- Holger H, Dagerlind A & Hokfelt T 1998 Immunohistochemical characterization of the peptidergic innervation of the rat adrenal gland. *Hormone and Metabolic Research* **30** 315–322. (doi:10.1055/s-2007-978891)
- Hornsby P & Crivello J 1983 The role of lipid peroxidation and biological antioxidants in the function of the adrenal cortex. Part 2. *Molecular and Cellular Endocrinology* **30** 123–147.
- Hornsby PJ & Gill GN 1977 Hormonal control of adrenocortical cell proliferation desensitization to ACTH and Interaction between ACTH and FGF in bovine adrenocortical cells in culture. *Journal of Clinical Investigation* **60** 342–352.
- Hornsby PJ, O'Hare MJ & Neville AM 1974 Functional and morphological observations on rat adrenal zona glomerulosa cells in monolayer culture. *Endocrinology* **95** 1240–1251.
- Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ, Stein E, Levine E, Delimpasi G, Hsiao HP *et al.* 2006 A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. *Nature Genetics* **38** 794–800. (doi:10.1038/ng1809)
- Hu J, Zhang Z, Shen WJ & Azhar S 2010 Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. *Nutrition and Metabolism* **7** e47. (doi:10.1186/1743-7075-7-47)
- Hughey JJ, Lee TK & Covert MW 2010 Computational modeling of mammalian signaling networks. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine* **2** 194–209. (doi:10.1002/wsbm.52)
- Isales CM, Zaidi M & Blair HC 2010 ACTH is a novel regulator of bone mass. *Annals of the New York Academy of Sciences* **1192** 110–116. (doi:10.1111/j.1749-6632.2009.05231.x)
- Iwen KA, Senyaman O, Schwartz A, Drenckhan M, Meier B, Hadaschik D & Klein J 2008 Melanocortin crosstalk with adipose functions: ACTH directly induces insulin resistance, promotes a pro-inflammatory adipokine profile and stimulates UCP-1 in adipocytes. *Journal of Endocrinology* **196** 465–472. (doi:10.1677/JOE-07-0299)
- Jackson DS, Ramachandrapa S, Clark AJ & Chan LF 2015 Melanocortin receptor accessory proteins in adrenal disease and obesity. *Frontiers in Neuroscience* **9** e213. (doi:10.3389/fnins.2015.00213)
- James ME, Chu KM, Clark AJ & King PJ 2008 Mechanisms of adrenocorticotropin-induced activation of extracellularly regulated kinase 1/2 mitogen-activated protein kinase in the human H295R

- adrenal cell line. *Endocrinology* **149** 1898–1905. (doi:10.1210/en.2007-0949)
- Jefcoate C 2002 High-flux mitochondrial cholesterol trafficking, a specialized function of the adrenal cortex. *Journal of Clinical Investigation* **110** 881–890. (doi:10.1172/JCI16771)
- Johnston H, King PJ & O'Shaughnessy PJ 2007 Effects of ACTH and expression of the melanocortin-2 receptor in the neonatal mouse testis. *Reproduction* **133** 1181–1187. (doi:10.1530/REP-06-0359)
- Kang MJ, Fujino T, Sasano H, Minekura H, Yabuki N, Nagura H, Iijima H & Yamamoto TT 1997 A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. *PNAS* **94** 2880–2884.
- Kapas S, Cammas FM, Hinson JP & Clark AJ 1996 Agonist and receptor binding properties of adrenocorticotropin peptides using the cloned mouse adrenocorticotropin receptor expressed in a stably transfected HeLa cell line. *Endocrinology* **137** 3291–3294.
- Karpac J, Ostwald D, Bui S, Hunnewell P, Shankar M & Hochgeschwender U 2005 Development, maintenance, and function of the adrenal gland in early postnatal proopiomelanocortin-null mutant mice. *Endocrinology* **146** 2555–2562. (doi:10.1210/en.2004-1290)
- Kem DC, Gomez-Sanchez C, Kramer NJ, Holland OB & Higgins JR 1975 Plasma aldosterone and renin activity response to ACTH infusion in dexamethasone-suppressed normal and sodium-depleted man. *Journal of Clinical Endocrinology & Metabolism* **40** 116–124. (doi:10.1210/jcem-40-1-116)
- Kilianova Z, Basora N, Kilian P, Payet MD & Gallo-Payet N 2006 Human MC2R expression and functionality. Effect of PKA and PKC on desensitization and internalization. *Endocrinology* **147** 2325–2337.
- Kim AC, Barlaskar FM, Heaton JH, Else T, Kelly VR, Krill KT, Scheys JO, Simon DP, Trovato A, Yang WH *et al.* 2009 In search of adrenocortical stem and progenitor cells. *Endocrine Reviews* **30** 241–263. (doi:10.1210/er.2008-0039)
- Kojima I, Kojima K & Rasmussen H 1985a Characteristics of angiotensin II-, K⁺- and ACTH-induced calcium influx in adrenal glomerulosa cells. *Journal of Biological Chemistry* **260** 9171–9176.
- Kojima I, Kojima K & Rasmussen H 1985b Role of calcium and cAMP in the action of adrenocorticotropin on aldosterone secretion. *Journal of Biological Chemistry* **260** 4248–4256.
- Kraemer FB 2007 Adrenal cholesterol utilization. *Molecular and Cellular Endocrinology* **265–266** 42–45. (doi:10.1016/j.mce.2006.12.001)
- Lacroix A, Feelders RA, Stratakis CA & Nieman LK 2015 Cushing's syndrome. *Lancet* **386** 913–927. (doi:10.1016/S0140-6736(14)61375-1)
- Le T & Schimmer BP 2001 The regulation of MAPKs in Y1 mouse adrenocortical tumor cells. *Endocrinology* **142** 4282–4287.
- Leal LF, Szarek E, Faucz F & Stratakis CA 2015 Phosphodiesterase 8B and cyclic AMP signaling in the adrenal cortex. *Endocrine* **50** 27–31. (doi:10.1007/s12020-015-0621-y)
- Lefkowitz RJ, Roth J & Pastan I 1970 Effects of calcium on ACTH stimulation of the adrenal: separation of hormone binding from adenyl cyclase activation. *Nature* **228** 864–866.
- Lefrançois-Martinez AM, Tournaire C, Martinez A, Berger M, Daoudal S, Tritsch D, Veyssiere G & Jean C 1999 Product of side-chain cleavage of cholesterol, isocaproaldehyde, is an endogenous specific substrate of mouse vas deferens protein, an aldose reductase-like protein in adrenocortical cells. *Journal of Biological Chemistry* **274** 32875–32880.
- Lefrançois-Martinez AM, Bertherat J, Val P, Tournaire C, Gallo-Payet N, Hyndman D, Veyssiere G, Bertagna X, Jean C & Martinez A 2004 Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors. *Journal of Clinical Endocrinology & Metabolism* **89** 3010–3019.
- Lenzini L, Caroccia B, Campos AG, Fassina A, Belloni AS, Seccia TM, Kuppasamy M, Ferraro S, Skander G, Bader M *et al.* 2014 Lower expression of the TWIK-related acid-sensitive K⁺ channel 2 (TASK-2) gene is a hallmark of aldosterone-producing adenoma causing human primary aldosteronism. *Journal of Clinical Endocrinology & Metabolism* **99** E674–E682. (doi:10.1210/jc.2013-2900)
- Li D & Sewer MB 2010 RhoA and DIAPH1 mediate adrenocorticotropin-stimulated cortisol biosynthesis by regulating mitochondrial trafficking. *Endocrinology* **151** 4313–4323. (doi:10.1210/en.2010-0044)
- Li CH, Chung D, Yamashiro D & Lee CY 1978 Isolation, characterization, and synthesis of a corticotropin-inhibiting peptide from human pituitary glands. *PNAS* **75** 4306–4309.
- Li ZG, Park D & LaBella FS 1989 Adrenocorticotropin(1-10) and -(11-24) promote adrenal steroidogenesis by different mechanisms. *Endocrinology* **125** 592–596.
- Liang L, Angleson JK & Does RM 2013 Using the human melanocortin-2 receptor as a model for analyzing hormone/receptor interactions between a mammalian MC2 receptor and ACTH(1-24). *General and Comparative Endocrinology* **181** 203–210. (doi:10.1016/j.ygcen.2012.11.011)
- Liu H, Enyeart JA & Enyeart JJ 2008 ACTH inhibits bTREK-1 K⁺ channels through multiple cAMP-dependent signaling pathways. *Journal of General Physiology* **132** 279–294. (doi:10.1085/jgp.200810003)
- Liu H, Enyeart JA & Enyeart JJ 2010 ACTH induces Cav3.2 current and mRNA by cAMP-dependent and cAMP-independent mechanisms. *Journal of Biological Chemistry* **285** 20040–20050. (doi:10.1074/jbc.M110.104190)
- Lotfi CF, Todorovic Z, Armelin HA & Schimmer BP 1997 Unmasking a growth-promoting effect of the adrenocorticotrophic hormone in Y1 mouse adrenocortical tumor cells. *Journal of Biological Chemistry* **272** 29886–29891.
- Louiset E, Duparc C, Young J, Renouf S, Tetsi Nomigni M, Boutelet I, Libe R, Bram Z, Groussin L, Caron P *et al.* 2013 Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. *New England Journal of Medicine* **369** 2115–2125. (doi:10.1056/NEJMoa1215245)
- Lymangrover JR 1980 Adrenocorticotrophic hormone and cyclic adenosine monophosphate effect on mouse adrenal cortical cell membrane potential. *Experientia* **36** 613–614.
- Maloberti P, Cornejo Maciel F, Castillo AF, Castilla R, Duarte A, Toledo MF, Meuli F, Mele P, Paz C & Podesta EJ 2007 Enzymes involved in arachidonic acid release in adrenal and Leydig cells. *Molecular and Cellular Endocrinology* **265–266** 113–120. (doi:10.1016/j.mce.2006.12.026)
- Manna PR, Dyson MT & Stocco DM 2009 Regulation of the steroidogenic acute regulatory protein gene expression: present and future perspectives. *Molecular Human Reproduction* **15** 321–333. (doi:10.1093/molehr/gap025)
- Manuelidis L & Mulrow P 1973 ACTH effects on aldosterone production and mitochondrial ultrastructure in adrenal gland cultures. *Endocrinology* **93** 1104–1108.
- Martinez A, Aigueperse C, Val P, Dussault M, Tournaire C, Berger M, Veyssiere G, Jean C & Lefrançois Martinez A 2001 Physiological functions and hormonal regulation of mouse vas deferens protein (AKR1B7) in steroidogenic tissues. *Chemico-Biological Interactions* **130–132** 903–917.
- Matthews E & Saffran M 1973 Ionic dependence of adrenal steroidogenesis and ACTH-induced changes in the membrane potential of adrenocortical cells. *Journal of Physiology* **234** 43–64.
- Mattos GE, Jacysyn JF, Amarante-Mendes GP & Lotfi CF 2011 Comparative effect of FGF2, synthetic peptides 1-28 N-POMC and ACTH on proliferation in rat adrenal cell primary cultures. *Cell and Tissue Research* **345** 343–356. (doi:10.1007/s00441-011-1220-8)

- Mazzocchi G, Malendowicz LK, Rebuffat P, Robba C, Gottardo G & Nussdorfer GG 1986 Short- and long-term effects of ACTH on the adrenal zona glomerulosa of the rat. A coupled stereological and enzymological study. *Cell and Tissue Research* **243** 303–310.
- McFarlane SI & Sowers JR 2003 Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. *Journal of Clinical Endocrinology & Metabolism* **88** 516–523.
- McNeill H, Whitworth E, Vinson GP & Hinson JP 2005 Distribution of extracellular signal-regulated protein kinases 1 and 2 in the rat adrenal and their activation by angiotensin II. *Journal of Endocrinology* **187** 149–157.
- Meimaridou E, Hughes CR, Kowalczyk J, Guasti L, Chapple JP, King PJ, Chan LF, Clark AJ & Metherell LA 2013 Familial glucocorticoid deficiency: new genes and mechanisms. *Molecular and Cellular Endocrinology* **371** 195–200. (doi:10.1016/j.mce.2012.12.010)
- Metherell LA, Chapple JP, Cooray S, David A, Becker C, Ruschendorf F, Naville D, Begeot M, Khoo B, Nurnberg P *et al.* 2005 Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. *Nature Genetics* **37** 166–170.
- Miller WL & Auchus RJ 2011 The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. *Endocrine Reviews* **32** 81–151. (doi:10.1210/er.2010-0013)
- Moller CL, Raun K, Jacobsen ML, Pedersen TA, Holst B, Conde-Frieboes KW & Wulff BS 2011 Characterization of murine melanocortin receptors mediating adipocyte lipolysis and examination of signalling pathways involved. *Molecular and Cellular Endocrinology* **341** 9–17. (doi:10.1016/j.mce.2011.03.010)
- Monticone S, Viola A, Tizzani D, Crudo V, Burrello J, Galmozzi M, Veglio F & Mulatero P 2012 Primary aldosteronism: who should be screened? *Hormone and Metabolic Research* **44** 163–169. (doi:10.1055/s-0031-1295409)
- Mountjoy K, Robbins L, Mortrud M & Cone R 1992 The cloning of a family of genes that encode the melanocortin receptors. *Science* **257** 1248–1251.
- Mountjoy KG, Bird IM, Rainey WE & Cone RD 1994 ACTH induces up-regulation of ACTH receptor mRNA in mouse and human adrenocortical cell lines. *Molecular and Cellular Endocrinology* **99** R17–R20.
- Mulatero P, Monticone S, Rainey WE, Veglio F & Williams TA 2013 Role of KCNJ5 in familial and sporadic primary aldosteronism. *Nature Reviews Endocrinology* **9** 104–112. (doi:10.1038/nrendo.2012.230)
- Muller J 1978 Suppression of aldosterone biosynthesis by treatment of rats with adrenocorticotropin: comparison with glucocorticoid effects. *Endocrinology* **103** 2061–2068.
- Murray SA, Davis K & Gay V 2003 ACTH and adrenocortical gap junctions. *Microscopy Research and Technique* **61** 240–246. (doi:10.1002/jemt.10332)
- Nanba K, Chen A, Nishimoto K & Rainey WE 2015 Role of Ca(2+)/calmodulin-dependent protein kinase kinase in adrenal aldosterone production. *Endocrinology* **156** 1750–1756. (doi:10.1210/en.2014-1782)
- Nicholls MG, Espiner EA & Donald RA 1975 Plasma aldosterone response to low dose ACTH stimulation. *Journal of Clinical Endocrinology & Metabolism* **41** 186–188. (doi:10.1210/jcem-41-1-186)
- Nishimoto K, Rigsby CS, Wang T, Mukai K, Gomez-Sanchez CE, Rainey WE & Seki T 2012 Transcriptome analysis reveals differentially expressed transcripts in rat adrenal zona glomerulosa and zona fasciculata. *Endocrinology* **153** 1755–1763. (doi:10.1210/en.2011-1915)
- Nishimoto K, Rainey WE, Bollag WB & Seki T 2013 Lessons from the gene expression pattern of the rat zona glomerulosa. *Molecular and Cellular Endocrinology* **371** 107–113. (doi:10.1016/j.mce.2012.12.023)
- Noon LA, Clark AJ & King PJ 2004 A peroxisome proliferator-response element in the murine mc2-r promoter regulates its transcriptional activation during differentiation of 3T3-L1 adipocytes. *Journal of Biological Chemistry* **279** 22803–22808.
- Norman D, Isidori AM, Frajese V, Caprio M, Chew SL, Grossman AB, Clark AJ, Michael Besser G & Fabbri A 2003 ACTH and alpha-MSH inhibit leptin expression and secretion in 3T3-L1 adipocytes: model for a central-peripheral melanocortin-leptin pathway. *Molecular and Cellular Endocrinology* **200** 99–109.
- Nussdorfer GG 1986 Cytophysiology of the adrenal cortex. International review of cytology, vol 98, pp 211–249. *Review of Cytology* **98** 211–249.
- Ota T, Fustin JM, Yamada H, Doi M & Okamura H 2012 Circadian clock signals in the adrenal cortex. *Molecular and Cellular Endocrinology* **349** 30–37. (doi:10.1016/j.mce.2011.08.010)
- Otis M, Campbell S, Payet MD & Gallo-Payet N 2007 Expression of extracellular matrix proteins and integrins in rat adrenal gland: importance for ACTH-associated functions. *Journal of Endocrinology* **193** 331–347. (doi:10.1677/JOE-07-0055)
- Ozata DM, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, Hoog A, Zedenius J, Backdahl M, Larsson C & Lui WO 2011 The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. *Endocrine-Related Cancer* **18** 643–655. (doi:10.1530/ERC-11-0082)
- Park SY, Walker JJ, Johnson NW, Zhao Z, Lightman SL & Spiga F 2013 Constant light disrupts the circadian rhythm of steroidogenic proteins in the rat adrenal gland. *Molecular and Cellular Endocrinology* **349** 114–123. (doi:10.1016/j.mce.2012.11.010)
- Pastel E, Pointud JC, Volat F, Martinez A & Lefrancois-Martinez AM 2012 Aldo-keto reductases 1B in endocrinology and metabolism. *Frontiers in Pharmacology* **3** 148. (doi:10.3389/fphar.2012.00148)
- Patel D, Boufragech M, Jain M, Zhang L, He M, Gesuwan K, Gulati N, Nilubol N, Fojo T & Kebebew E 2013 MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. *Surgery* **154** 1224–1229. (doi:10.1016/j.surg.2013.06.022)
- Payet MD, Benabderrazik M & Gallo-Payet N 1987 Excitation-secretion coupling: ionic currents in glomerulosa cells: effects of adrenocorticotropin and K⁺ channel blockers. *Endocrinology* **121** 875–882.
- Payet MD, Durroux T, Bilodeau L, Guillon G & Gallo-Payet N 1994 Characterization of K⁺ and Ca²⁺ ionic currents in glomerulosa cells from human adrenal glands. *Endocrinology* **134** 2589–2598.
- Penhoat A, Jaillard C & Saez JM 1989 Corticotropin positively regulates its own receptors and cAMP response in cultured bovine adrenal cells. *PNAS* **86** 4978–4981.
- Pihlajoki M, Dorner J, Cochran RS, Heikinheimo M & Wilson DB 2015 Adrenocortical zonation, renewal, and remodeling. *Frontiers in Endocrinology* **6** 27. (doi:10.3389/fendo.2015.00027)
- Poderoso C, Converso DP, Maloberti P, Duarte A, Neuman I, Galli S, Cornejo Maciel F, Paz C, Carreras MC, Poderoso JJ *et al.* 2008 A mitochondrial kinase complex is essential to mediate an ERK1/2-dependent phosphorylation of a key regulatory protein in steroid biosynthesis. *PLoS One* **3** e1443. (doi:10.1371/journal.pone.0001443)
- Pudney J, Price GM, Whitehouse BJ & Vinson GP 1984 Effects of chronic ACTH stimulation on the morphology of the rat adrenal cortex. *Anatomical Record* **210** 603–615. (doi:10.1002/ar.1092100408)
- Raffin-Sanson ML, de Keyser Y & Bertagna X 2003 Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions. *European Journal of Endocrinology* **149** 79–90.
- Rainey WE 1999 Adrenal zonation: clues from 11 β -hydroxylase and aldosterone synthase. *Molecular and Cellular Endocrinology* **151** 151–160.
- Rainey WE, Saner K & Schimmer BP 2004 Adrenocortical cell lines. *Molecular and Cellular Endocrinology* **228** 23–38. (doi:10.1016/j.mce.2003.12.020)

- Rani CS, Keri G & Ramachandran J 1983 Studies on corticotropin-induced desensitization of normal rat adrenocortical cells. *Endocrinology* **112** 315–320.
- Rayfield EJ, Rose LI, Dluhy RG & Williams GH 1973 Aldosterone secretory and glucocorticoid excretory responses to alpha 1-24 ACTH (Cortrosyn) in sodium-depleted normal man. *Journal of Clinical Endocrinology & Metabolism* **36** 30–35. (doi:10.1210/jcem-36-1-30)
- Rebuffat P, Cavallini L, Belloni AS, Mazzocchi G, Coi A, De Tos GP & Nussdorfer GG 1989 A morphometric study of the reversal of ACTH-induced hypertrophy of rat adrenocortical cells after cessation of treatment. *Journal of Submicroscopic Cytology and Pathology* **21** 73–81.
- Rege J, Nakamura Y, Wang T, Merchen TD, Sasano H & Rainey WE 2014 Transcriptome profiling reveals differentially expressed transcripts between the human adrenal zona fasciculata and zona reticularis. *Journal of Clinical Endocrinology & Metabolism* **99** E518–E527. (doi:10.1210/jc.2013-3198)
- Resendis-Antonio O, Gonzalez-Torres C, Jaime-Munoz G, Hernandez-Patino CE & Salgado-Munoz CF 2015 Modeling metabolism: a window toward a comprehensive interpretation of networks in cancer. *Seminars in Cancer Biology* **30** 79–87. (doi:10.1016/j.semcancer.2014.04.003)
- Riondel AM, Rebuffat P, Mazzocchi G, Nussdorfer GG, Gaillard RC, Bockhorn L, Nussberger J, Vallotton MB & Muller AF 1987 Long-term effects of ACTH combined with angiotensin II on steroidogenesis and adrenal zona glomerulosa morphology in the rat. *Acta Endocrinologica* **114** 47–54.
- Rocchi S, Gaillard I, van Obberghen E, Chambaz E & Vilgrain I 2000 Adrenocorticotrophic hormone stimulates phosphotyrosine phosphatase SHP2 in bovine adrenocortical cells: phosphorylation and activation by cAMP-dependent protein kinase. *Biochemical Journal* **352** Part 2 483–490.
- Rone MB, Fan J & Papadopoulos V 2009 Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. *Biochimica et Biophysica Acta* **1791** 646–658. (doi:10.1016/j.bbalip.2009.03.001)
- Roy S, Pinard S, Chouinard L & Gallo-Payet N 2011 Adrenocorticotropin (ACTH) effects on MAPK phosphorylation in human fasciculata cells and in embryonic kidney 293 cells expressing human melanocortin 2 receptor (MC2R) and MC2R accessory protein (MRAP)beta. *Molecular and Cellular Endocrinology* **336** 31–40.
- Roy S, Rached M & Gallo-Payet N 2007 Differential regulation of the human adrenocorticotropin receptor [melanocortin-2 receptor (MC2R)] by human MC2R accessory protein isoforms alpha and beta in isogenic human embryonic kidney 293 cells. *Molecular Endocrinology* **21** 1656–1669. (doi:10.1016/j.mce.2010.12.030)
- Russell GM, Kalafatakis K & Lightman SL 2014 The importance of biological oscillators for hypothalamic-pituitary-adrenal activity and tissue glucocorticoid response: coordinating stress and neurobehavioural adaptation. *Journal of Neuroendocrinology* **27** 378–388. (doi:10.1111/jne.12247)
- Samuels M, Gallo-Payet N, Pinard S, Hasselmann C, Magne F, Patry L, Chouinard L, Schwartztruber J, René P, Sawyer N *et al.* 2013 Bioinactive ACTH Causing Glucocorticoid Deficiency. *Journal of Clinical Endocrinology & Metabolism* **98** 736–742.
- Sarkar D, Imai T, Kambe F, Shibata A, Ohmori S, Siddiq A, Hayasaka S, Funahashi H & Seo H 2001 The human homolog of *Diminuto*/Dwarf1 gene (*hDiminuto*): a novel ACTH-responsive gene overexpressed in benign cortisol-producing adrenocortical adenomas. *Journal of Clinical Endocrinology & Metabolism* **86** 5130–5137.
- Schauer E, Trautinger F, Kock A, Schwarz A, Bhardwaj R, Simon M, Ansel JC, Schwarz T & Luger TA 1994 Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. *Journal of Clinical Investigation* **93** 2258–2262. (doi:10.1172/JCI117224)
- Schiebinger RJ, Braley LM, Menachery A & Williams GH 1985 Calcium, a “third messenger” of cAMP-stimulated adrenal steroid secretion. *American Journal of Physiology* **248** E89–E94.
- Schimmer BP & White PC 2010 Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. *Molecular Endocrinology* **24** 1322–1337. (doi:10.1210/me.2009-0519)
- Schimmer BP, Cordova M, Cheng H, Tsao A, Goryachev AB, Schimmer AD & Morris Q 2006 Global profiles of gene expression induced by adrenocorticotropin in Y1 mouse adrenal cells. *Endocrinology* **147** 2357–2367. (doi:10.1210/en.2005-1526)
- Schimmer BP, Cordova M, Cheng H, Tsao A & Morris Q 2007 A genome-wide assessment of adrenocorticotropin action in the Y1 mouse adrenal tumor cell line. *Molecular and Cellular Endocrinology* **265–266** 102–107. (doi:10.1016/j.mce.2006.12.024)
- Sebag JA & Hinkle PM 2010 Regulation of G protein-coupled receptor signaling: specific dominant-negative effects of melanocortin 2 receptor accessory protein 2. *Science Signaling* **3** ra28. (doi:10.1126/scisignal.2000593)
- Seelig S, Sayers G, Schwyzer R & Schiller P 1971 Isolated adrenal cells: ACTH(11-24), a competitive antagonist of ACTH(1-39) and ACTH (1-10). *FEBS Letters* **19** 232–234.
- Seely EW, Conlin PR, Brent GA & Dluhy RG 1989 Adrenocorticotropin stimulation of aldosterone: prolonged continuous versus pulsatile infusion. *Journal of Clinical Endocrinology & Metabolism* **69** 1028–1032. (doi:10.1210/jcem-69-5-1028)
- Seidah NG & Chretien M 1999 Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. *Brain Research* **848** 45–62.
- Sewer MB & Li D 2008 Regulation of steroid hormone biosynthesis by the cytoskeleton. *Lipids* **43** 1109–1115. (doi:10.1007/s11745-008-3221-2)
- Sewer MB & Waterman MR 2003 ACTH modulation of transcription factors responsible for steroid hydroxylase gene expression in the adrenal cortex. *Microscopy Research and Technique* **61** 300–307.
- Shen T, Suzuki Y, Poyard M, Best-Belpomme M, Defer N & Hanoune J 1997 Localization and differential expression of adenylyl cyclase messenger ribonucleic acids in rat adrenal gland determined by *in situ* hybridization. *Endocrinology* **138** 4591–4598.
- Si J, Ge Y, Zhuang S, Wang LJ, Chen S & Gong R 2013 Adrenocorticotrophic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. *Kidney International* **83** 635–646. (doi:10.1038/ki.2012.447)
- Slominski A, Ermak G, Hwang J, Mazurkiewicz J, Corliss D & Eastman A 1996a The expression of proopiomelanocortin (POMC) and of corticotropin releasing hormone receptor (CRH-R) genes in mouse skin. *Biochimica et Biophysica Acta* **1289** 247–251.
- Slominski A, Ermak G & Mihm M 1996b ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin. *Journal of Clinical Endocrinology & Metabolism* **81** 2746–2749. (doi:10.1210/jcem.81.7.8675607)
- Smith SR, Gawronska-Kozak B, Janderova L, Nguyen T, Murrell A, Stephens JM & Mynatt RL 2003 Agouti expression in human adipose tissue: functional consequences and increased expression in type 2 diabetes. *Diabetes* **52** 2914–2922.
- Son GH, Chung S, Choe HK, Kim HD, Baik SM, Lee H, Lee HW, Choi S, Sun W, Kim H *et al.* 2008 Adrenal peripheral clock controls the autonomous circadian rhythm of glucocorticoid by causing rhythmic steroid production. *PNAS* **105** 20970–20975. (doi:10.1073/pnas.0806962106)
- Stocco DM 2000 The role of the StAR protein in steroidogenesis: challenges for the future. *Journal of Endocrinology* **164** 247–253.
- Stocco DM, Wang X, Jo Y & Manna PR 2005 Multiple signaling pathways regulating steroidogenesis and steroidogenic acute regulatory protein expression: more complicated than we thought. *Molecular Endocrinology* **19** 2647–2659. (doi:10.1210/me.2004-0532)

- Szalay KS, De Wied D & Stark E 1989 Effects of ACTH-(11-24) on the corticosteroid production of isolated adrenocortical cells. *Journal of Steroid Biochemistry* **32** 259–262.
- Tabares L & Lopez-Barneo J 1986 Calcium action potentials in cultured adrenocortical cells. *Pflügers Archiv* **407** 163–165.
- Talaber G, Tuckermann JP & Okret S 2015 ACTH controls thymocyte homeostasis independent of glucocorticoids. *FASEB Journal* **29** 2526–2534. (doi:10.1096/fj.14-268508)
- Thomas M, Keramidas M, Monchaux E & Feige JJ 2004 Dual hormonal regulation of endocrine tissue mass and vasculature by adrenocorticotropin in the adrenal cortex. *Endocrinology* **145** 4320–4329.
- Tremblay E, Payet MD & Gallo-Payet N 1991 Effects of ACTH and angiotensin II on cytosolic calcium in cultured adrenal glomerulosa cells. Role of cAMP production in the ACTH effect. *Cell Calcium* **12** 655–673.
- Tsai LC & Beavo JA 2011 The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis. *Current Opinion in Pharmacology* **11** 670–675. (doi:10.1016/j.coph.2011.09.003)
- Ulrich-Lai YM, Arnhold MM & Engeland WC 2006a Adrenal splanchnic innervation contributes to the diurnal rhythm of plasma corticosterone in rats by modulating adrenal sensitivity to ACTH. *American Journal of Physiology: Regulatory, Integrative and Comparative Physiology* **290** R1128–R1135. (doi:10.1152/ajpregu.00042.2003)
- Ulrich-Lai YM, Figueiredo HF, Ostrander MM, Choi DC, Engeland WC & Herman JP 2006b Chronic stress induces adrenal hyperplasia and hypertrophy in a subregion-specific manner. *American Journal of Physiology: Endocrinology and Metabolism* **291** E965–E973. (doi:10.1152/ajpendo.00070.2006)
- Van Cauter E, Spiegel K, Tasali E & Leproult R 2008 Metabolic consequences of sleep and sleep loss. *Sleep Medicine* **9** (Supplement 1) S23–S28. (doi:10.1016/S1389-9457(08)70013-3)
- Vinson GP 2003 Adrenocortical zonation and ACTH. *Microscopy Research and Technique* **61** 227–239.
- Vinson GP & Brennan CH 2013 Addiction and the adrenal cortex. *Endocrine Connections* **2** R1–R14. (doi:10.1530/EC-13-0028)
- Vinson G & Hinson J 1992 Blood flow and hormone secretion in the adrenal gland. In *The Adrenal Gland*, pp 71–104. Ed VHT James. New York, NY, USA: Raven Press.
- Vinson GP, Hinson JP & Toth IE 1994 The neuroendocrinology of the adrenal cortex. *Journal of Neuroendocrinology* **6** 235–246.
- Vrezas I, Willenberg HS, Mansmann G, Hiroi N, Fritzen R & Bornstein SR 2003 Ectopic adrenocorticotropin (ACTH) and corticotropin-releasing hormone (CRH) production in the adrenal gland: basic and clinical aspects. *Microscopy Research and Technique* **61** 308–314. (doi:10.1002/jemt.10340)
- Wang XJ, Dyson MT, Jo Y, Eubank DW & Stocco DM 2003 Involvement of 5-lipoxygenase metabolites of arachidonic acid in cyclic AMP-stimulated steroidogenesis and steroidogenic acute regulatory protein gene expression. *Journal of Steroid Biochemistry and Molecular Biology* **85** 159–166.
- Williams GH, Cain JP, Dluhy RG & Underwood RH 1972 Studies of the control of plasma aldosterone concentration in normal man. I. Response to posture, acute and chronic volume depletion, and sodium loading. *Journal of Clinical Investigation* **51** 1731–1742. (doi:10.1172/JCI106974)
- Wolkersdorfer G & Bornstein S 1998 Tissue remodelling in the adrenal gland. *Biochemical Pharmacology* **56** 193–171.
- Xing Y, Parker CR, Edwards M & Rainey WE 2010 ACTH is a potent regulator of gene expression in human adrenal cells. *Journal of Molecular Endocrinology* **45** 59–68. (doi:10.1677/JME-10-0006)
- Xing Y, Edwards MA, Ahlem C, Kennedy M, Cohen A, Gomez-Sanchez CE & Rainey WE 2011 The effects of ACTH on steroid metabolomic profiles in human adrenal cells. *Journal of Endocrinology* **209** 327–335. (doi:10.1530/JOE-10-0493)
- Zaidi M, Sun L, Robinson LJ, Tourkova IL, Liu L, Wang Y, Zhu LL, Liu X, Li J, Peng Y *et al.* 2010 ACTH protects against glucocorticoid-induced osteonecrosis of bone. *PNAS* **107** 8782–8787. (doi:10.1073/pnas.0912176107)

Received in final form 12 January 2016

Accepted 21 January 2016

Accepted Preprint published online 21 January 2016